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ABSTRACT 
Hypertension is the most common chronic disease in the world, yet the precise cause of 
elevated blood pressure (BP) often cannot be determined. Animal models have been useful for 
unraveling the pathogenesis of hypertension and for testing novel therapeutic strategies. The 
utility of animal models for improving understanding of the pathogenesis, prevention, and 
treatment of hypertension and its comorbidities depends on their validity for representing human 
forms of hypertension, including responses to therapy, as well as on the quality of studies in 
those models (such as reproducibility and experimental design). Important unmet needs in this 
field include development of models that mimic the discrete hypertensive syndromes that now 
populate the clinic (such as primary aldosteronism), a necessity to resolve ongoing controversies 
regarding the pathogenesis of hypertension, and developing new avenues for preventing and 
treating hypertension and its complications. Animal models may indeed be useful for addressing 
these unmet needs. 
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CLINICAL PROBLEM AND UNMET NEEDS  
Hypertension is the most common chronic disease in the world, and producesing substantial 
morbidity and mortality.  Yet, in the majority of individuals, the precise cause of elevated blood 
pressure (BP) cannot be determined. Risk factors for primary (formerly called ‘essential’) 
hypertension include advancing age, obesity, high dietary NaCl consumption, and low dietary 
potassium intake, however although these appear to contribute to, but not cause, hypertension. 
Renin-sodium profiling has been used to classify primary hypertension, suggesting that the 
phenotype is highly variable, but treatment remains largely empirical, and influenced by race and 
comorbid disease.   
A number of hypertensive subtypes also exist, and while they may comprise only a small 
percentage fraction of individuals with hypertension, they can nonetheless be relatively common, 
given the broad prevalence of hypertension itself.  Malignant hypertension is related to, but 
pathophysiologically distinct from, primary hypertension, as is the syndrome of preeclampsia.  
Genetic forms of hypertension with Mendelian inheritance are rare, but have helped to identify 
important blood pressure (BP) regulating pathways.  Secondary causes may involve the renal 
vasculature, endocrine organs, and the kidney, and may comprise up to 20% of cases of resistant 
hypertension.  Finally, an increasing number of drugs used to treat cancer and other conditions 
are now recognized as causing hypertension, which is often severe. Genetic forms of 
hypertension with Mendelian inheritance are rare, but have helped to identify important blood 
pressure (BP) regulating pathways.  Over the past 20 years, some the most important scientific 
breakthroughs have emanated from discovering the basis of rare subtypes of human 
hypertension. Among these are the solution of nearly all the monogenic causes of hypertension; 
identification of discrete somatic mutations that cause primary aldosteronism; the discovery that 
polymorphisms in the APOL1 gene underlie some racial disparities in hypertensive kidney 
disease; the discovery that placental insufficiency generates placental growth factor and 
soluble fms-like tyrosine kinase-1 (sFlt-1), factors that mark and contribute to preeclampsia; and 
finally, the recognition that certain anti-cancer drugs commonly cause hypertension by disrupting 
impairing the function of the vascular endothelium and the glomerulus. 
The initial animal models of hypertension to be developed involved constriction of renal 
arteries (‘Goldblatt kidney’) or parenchyma (Page Kidneys); the pathophysiology closely 
mimicked their human analogs. Yet, renovascular hypertension and ‘Page kidneys’ represent 
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only a small fraction of human hypertension.  Most experimental studies of hypertension using 
animals, therefore, have focused on understanding mechanisms of primary hypertension.   
While excellent animal models with good human fidelity have been developed for many of 
these rare causes of hypertension (1, 2), models of primary hypertension have been more difficult 
to develop, largely because the causes of the human disorder are not unclear. Of NIH-sponsored 
hypertension research, studies using angiotensin (ANG)- II infusion comprise a disproportionate 
share (nearly 50%) (3).  Only 4% of studies focus on aging, and 4% on deoxycorticosterone 
acetate (DOCA)-salt hypertension (which even itself does not model primary aldosteronism).  
Thus, an important unmet need is to develop better animal models that more closely mimic the 
discrete hypertensive syndromes that now populate the clinic, such as primary aldosteronism.  A 
corollary would be that the portfolio of hypertension research might more closely mimic the 
spectrum of human hypertension.   
A second important unmet need is to resolve ongoing controversies regarding pathogenesis. 
Proponents for individual pathways including the primacy of the nervous system, kidney, and 
vasculature in development of hypertension typically focused on their own views and interests, 
often independent of considerations of heritability, environmental exposure, and developmental 
programming.  Despite more than 50 years of work, there is no consensus integrating this range 
of contributing causative factors.  This persistent lack of convergence slows bona fide progress 
and can limit the impact of the field. Addressing this unmet need will require that we bring 
together diverse teams, with competing views, who are committed to this common goal. 
THE UTILITY AND VALIDITY OF ANIMAL MODELS OF HYPERTENSION  
Across a range of human diseases including hypertension, animal models have been useful for 
unraveling disease pathogenesis, providing incisive experimental strategies not possible in 
human studies. In hypertension, the utility of animal models for improving understanding of the 
pathogenesis, prevention, and treatment of hypertension and its comorbidities depends on: 1) 
their validity for representing human forms of hypertension, including responses to therapy, and 
2) the quality of studies in those models. Recently, the utility of animal studies in translational 
medical research has come under increasing scrutiny because of low study reproducibility and 
problems such as bias, poor experimental design and execution, analytical and logical errors, and 
incomplete reporting. (4-8). Published recommendations on ways to mitigate these issues should 
be considered for any studies utilizing animal models. It should be noted that over 1000 scientific 
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journals have endorsed guidelines designed to improve the reporting of animal experiments.  
Nonetheless, these should be applied cautiously, as excessive regulation may also hinder studies 
in animals. 
Various criteria have been used to assess the utility of animal models in translational medical 
research, including “face” validity, “construct” validity, and “predictive” validity (9).(9) By 
conventional definition, each animal model of hypertension has at least some rudimentary degree 
of “face” validity in that each demonstrates the primary diagnostic feature, an increase in BP 
compared to a level deemed to be normal. However, some models may have greater face validity 
than others with respect to other phenotypic aspects of hypertension, like age of onset, temporal 
course, severity, variability, and associated comorbidities. Given the clinical importance of 
hypertension-related target organ damage, it is noteworthy that models are also available 
exhibiting face validity with respect to risk for hypertension-related disturbances, such as left 
ventricular hypertrophy (LVH), metabolic abnormalities, heart failure, renal damage, and stroke 
(e.g., spontaneously hypertensive rats [SHR], Dahl salt sensitive ([DSS] rats).(10-16) However, 
other hypertension-associated conditions, such as spontaneous development of atherosclerosis, 
angina, andor acute myocardial infarction, are not typically observed in current models.    
While all typical animal models uniformly exhibit increased BP, the models vary considerably 
with respect to “construct” validity, defined by how faithfully they recapitulate key features of 
human hypertension such as genetic and environmental triggers or key pathophysiologic 
mechanisms. As in other fields, there is no ideal animal model of human hypertension, as all 
have inherent limitations in construct validity. For example, there are striking differences 
between humans and animals with respect to factors that influence BP, including genetics, 
physiology, anatomy, behavior, environmental conditions and triggers, etc. The nature of these 
differences, particularly between humans and rodents, has motivated efforts to study 
hypertension and related disorders in larger animals and non-human primates. In addition, it 
should be emphasized that the validity or utility of BP studies in animal models may be 
compromised by using BP measurement techniques involving anesthesia or other forms of stress, 
or those that do not allow for adequate assessment of BP over 24 hours and of key features of the 
BP wave form, including both systolic and diastolic pressure, as these may influence risk for 
cardiovascular events (17-19). 
Predictive Validity and the Primary Reason for using Animal Models in Hypertension Research 
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The main goal of studying animal models of hypertension is to help develop improved 
approaches to preventing and treating high BP and its complications. Therefore, from a practical 
perspective, the most important aspect of such a model is “predictive” validity, defined by its 
value for guiding development of effective preventive or therapeutic interventions in humans. 
This raises several corollaries. What are the major obstacles and unmet needs for effectively 
preventing and treating hypertension and its complications? How useful are studies in a 
particular animal model(s) of hypertension for addressing these unmet needs? Some of the 
obstacles to achieving effective BP control and reduction of associated cardiovascular risk are 
related to behavioral issues leading to poor adherence to therapies or preventive measures, where 
application of animal models is unlikely to be productive. 
On the other hand, the problem of resistant hypertension is an area where animal models 
could have significant utility.  Even in patients thought to be taking the requisite antihypertensive 
drugs as prescribed, the prevalence of treatment-resistant hypertension is estimated to be in the 
range of 10-15% (20). While this may well be an overestimate, many individuals could still 
benefit from availability of new therapies, particularly since this group of patients is at high risk 
for complications of hypertension. Development of successful vaccines or device-based therapies 
could be particularly helpful for improving BP control in patients who cannot be controlled with 
conventional therapies, are not adherent to antihypertensive treatments, or in those being 
prescribed suboptimal therapies. It is also conceivable that new antihypertensive therapies might 
reduce the sizeable cardiovascular risk that persists in treated hypertensive patients with 
seemingly good BP control and other determinants of cardiovascular disease. While traditional 
antihypertensive agents do not necessarily completely abolish the cardiovascular risk of the 
treated hypertensive patient (21), further research is required to determine the extent to which 
such residual risk is related to unrecognized inadequate BP control, or to some underlying 
mechanism of hypertension that is conferring increased cardiovascular risk beyond just effects of 
elevated BP. While better approaches addressing the issue of suboptimal BP control are required, 
important unmet needs exist for developing new avenues for treating hypertension and its 
complications (19-22). (19-22) Animal models may indeed be useful for addressing these unmet 
needs. 
Predictive Value of Animal Models for Improving Management of Hypertension 
The utility of animal models for developing better approaches to the prevention and treatment 
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of human disease has been controversial. A major concern is the poor success rate for new drugs 
advanced to clinical trials on the basis of pre-clinical studies in animal models (9).(9) However, 
On the other hand, animal models have a verified track record in some human disorders, 
including hypertension, where all clinically effective antihypertensive drugs lower BP (9).  In 
this regard, all major classes of antihypertensive drugs in use today have been demonstrated to 
substantially reduce BP in one or more of the most commonly used animal models of 
hypertension (SHR, DSS rat, renal artery stenosis, mineralocorticoid-salt model) (10, 22).(10, 
22) For example, the SHR responds to the antihypertensive effects of almost all classes of drugs 
approved for treatment of hypertension. Because hypertension is a multifactorial heterogeneous 
disorder, and pharmacokinetic/pharmacodynamic variables may also vary among models, the 
magnitude of the BP response to a given antihypertensive treatment can vary greatly among 
animal models, just as among different patient subgroups. The availability of a wide variety of 
animal models is advantageous for generating hypotheses regarding the pathogenesis, 
prevention, and treatment of different forms of high BP in humans. Nonetheless, some 
approaches to lowering BP were apparently first tested in humans (e.g., ablation of sympathetic 
nerves, diet therapies, weight reduction, or supplemental potassium, and various drugs) 
questioning the need for research on animal models of human disorders. (23). Finally, because 
the main goal of treating hypertension is reducing risk for devastating cardiovascular 
complications, one could argue that the most valuable animal models should provide insights 
into prevention and treatment of these complications. 
Since understanding of the pathogenesis of human hypertension remains obscure, attempts to 
generalize study observations from a single animal model to the human circumstance should be 
viewed with considerable skepticism.  Ideally, studies in multiple models may be most helpful in 
providing a more complete view of the potential clinical relevance of mechanisms and 
therapeutic responses observed in experimental studies of hypertension, and in stimulating 
hypotheses about responses in subsets of hypertensive humans Nevertheless, studies in animal 
models of hypertension have successfully tested important hypotheses relevant to human 
hypertension, and have motivated clinical research studies leading to significant improvements in 
clinical management and outcomes, such as key applications of angiotensin converting enzyme 
inhibitors, (24, 25), dihydropyridine calcium channel blockers, angiotensin receptor blockers, 
and renin inhibitors to hypertension treatment. The history of the development of renin inhibitors 
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illustrates both the value and potential pitfalls of using animal models of hypertension to predict 
BP lowering effects of new molecules in hypertensive humans. Because of species differences in 
drug pharmacokinetics and in the amino acid sequence of renin especially in rodents, results in 
both non-primate and primate models were critical for defining applications of these agents in 
humans. (26-28). Overall, translational research in animal models of hypertension has largely 
been a success story in of modern medicine.  We suggest that judicious use of such models will 
continue to guide successful identification and advancement of interventions. 
LARGE VS. SMALL ANIMAL MODELS OF HYPERTENSION  
In selecting the most appropriate model of hypertension, one of the first decisions facing 
researchers is the choice between small and large animal models. Several factors must be 
considered, including the research scope and objectives, institutional resources, experimental 
cost, animal welfare, and practical suitability. The pros and cons of these models need to be 
thoroughly evaluated to select the best model to meet a particular research purpose (Table A).  
Small animal models are most commonly employed to study hypertension, providing useful 
insights. For example, these models may target specific factors implicated in the pathogenesis of 
human hypertension, including salt sensitivity, activation of the renin-angiotensin-aldosterone 
system (RAAS), and genetic factors. Rats and mice offer several advantages over larger animal 
models, like cost effectiveness, short gestation period, and tractability for genetic manipulation. 
However, reliable measurement of BP is challenging in small animals, surgical procedures are 
technically difficult, and the amount of sample available, particularly plasma and urine, may be 
limiting. Nevertheless, recent advances in imaging and surgical interventions have addressed 
some of these issues and have greatly streamlined the assessment of target organ damage (29).  
One of the most significant advantages of rodent models is ready availability of techniques for 
precise genetic alterations through whole-body or cell-specific gene deletions (knockout) or gene 
editing, allowing mechanistic studies to elucidate molecular mechanisms and identify novel 
targets for therapy, which are further enhanced by the relatively larger availability of specific 
antibodies for molecular studies compared to large animals. One great advantage of the rat is the 
existence of numerous genetic strains exhibiting robust spontaneous hypertensive phenotypes at 
baseline or through induction by environmental conditions. In addition, the rat is easy and cost 
effective to maintain, house and breed, yet large enough for most analytical studies, including 
long term, dynamic cardiovascular monitoring, and blood and tissue sampling.  Since these rat 
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models exhibit many phenotypic characteristics observed in human hypertension, they have been 
widely used to examine both the genetic and the mechanistic basis of hypertension. In recent 
years, many of these physiological monitoring techniques have been adapted to mice, which bear 
lower experimental and maintenance costs compared to rats.  In addition, there is a very wide 
range of specific antibodies available commercially for mouse that can be used for monitoring 
and in vivo treatment studies. 
Major advantages of large animal models, such as pig and primate, are their anatomical, 
physiological, and hemodynamic similarities to humans, combined with developmental 
pathophysiology in general, and specifically of hypertension, that may also more closely 
resemble humans compared to small animal models. They are alsoThe major advantage of large 
animal models, such as pig and primate, are their anatomical, physiological, and hemodynamic 
similarities to humans, where pathophysiology of hypertension may also more closely resemble 
humans, compared to small animal models (Table A). Large animals are particularly suitable for 
linear studies of hemodynamic consequences of long-term elevation of BP, with the added 
advantage of opportunities for repeated sampling of plasma and abundant tissues in which to 
quantify and often follow functional and structural injury in target organs in vivo and ex 
vivofunctional and structural injury in target organs.  Hence, integrated longitudinal data may be 
obtained in the same animal. A major disadvantage, however, is limited availability of 
genetically modified large animal models of hypertension compared to the breadth of genetically 
modified rodents. This is largely related to the higher costs of maintenance, longer reproductive 
cycles, and labor-intensive experiments in large animals. Along with lack of other reagents such 
as specific antibodies, this restricts the mechanistic depth of some studies using large animals.  
Finally, ethical issues have been raised for studies utilizing non-human primates.  
The most frequently used large animals for hypertension studies are the swine, non-human 
primates, sheep, and to a declining extent, dogs. The means to induce hypertension generally 
require pharmacological or surgical approaches. Pharmacological interventions using chronic 
infusions of Ang II, glucocorticoids, or DOCA (with and without high-salt diet) in pigs or dogs 
(30-33) are less frequently used than in smaller animals, partly due to the high cost of body-size 
titrated doses of drugs required over prolonged periods of time. On the other hand, surgical 
induction of hypertension is relatively simple, widely used, well tolerated, and carries a low risk 
for surgery-related mortality. These interventions include constriction of the aorta by extra-
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vascular banding (34), implantable adjustable occluders in the supra-renal aorta (35, 36) or renal 
arteries (37, 38), or intra-vascular devices in the renal arteries (39). These methods provide 
reliable models of chronic hypertension primarily of renovascular origin. The use of adjustable 
occluders to restrict blood flow afford controlling the degree of insult leading to hypertension, 
which provides opportunities for determining the extent of BP elevation required to trigger target 
organ injury and understanding how the process of end-organ damage unfolds. Intra-arterial 
devices such as coils (39, 40) that induce a progressive narrowing of the renal arterial lumen may 
mirror the obstructive role of plaques in human renal artery stenosis, and thus more closely 
recapitulate the pathophysiology of this well-documented clinical condition. Unlike adjustable 
occluders, the resulting degree of obstruction and target organ injury achieved by intra-vascular 
devices is often variable, again mimicking the clinical course of disease development. Finally, 
recent data show the potential of the African green monkey as a model of spontaneous 
hypertension (41). Hypertension in this model seems to develop without the need of external 
interventions, exacerbates with aging, and is associated with target organ injury, which may offer 
a new avenue for translational hypertension research. 
PLATFORMS OF EXPERIMENTAL HYPERTENSION: GENETIC  
Genetic Rat Models of Hypertension  
The complex nature of hypertensive phenotypes in combination with the polygenic mode of 
inheritance of hypertension requires appropriate models amenable to study.  Great insight has 
been gained from genetic studies of human hypertension and from mechanistic studies in 
experimental animal models of hypertension, summarized in other sections in this Statement. 
A number of rat genetic models of hypertension that have been utilized in genetic, (patho)-
physiological, and pharmacological studies (42-46).  Rat strains exhibiting genetic hypertension 
include the SHR, DSS rat, the Fawn Hooded Hypertensive rat (FHH), the Milan Hypertensive 
Strain (MHS), the Lyon Hypertensive (LH) rat, the Sabra Hypertensive (SH) rat, the Genetically 
Hypertensive (GH) rat, and the Inherited Stress-Induced Arterial Hypertension rats (ISIAH) 
model. Of these, the most commonly studied is the SHR; in the past 10 years, over 4500 articles 
were indexed in PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) under the term 
“Spontaneously Hypertensive Rats”.  In contrast, the next most commonly cited model, the 
“Dahl Salt Sensitive Rat”, was indexed 585 times over the same time span, while the other 
genetic rat strains were indexed less frequently. In addition to the above-described inbred strains, 
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there are a number of congenic and transgenic animals exhibiting hypertensive phenotypes. 
While too numerous to conveniently list in this space, these other strains are commonly based 
upon the genetic background of the major strains listed above. The following section provides a 
brief overview of the origin of a number of these strains, their general experimental applications, 
considerations for choosing a rat genetic model of hypertension, and the advantages and 
limitations of rat models. 
Commonly Utilized Strains: The majority of the genetically hypertensive rats have been 
derived from outbred Wistar or Sprague-Dawley breeding stock with selection for hypertension-
related traits.  These models provide reliable and reproducible phenotypes that are often 
representative of clinical observations. The severity of hypertension and of related phenotypes is 
different among strains and can be a consideration when choosing an animal for study; a number 
of reviews and resources provide comprehensive information (42-46).  Moreover, direct 
comparisons of the hypertensive phenotypes and general body characteristics of several of the 
genetic strains provide insight into the different degree of disease attained under similar 
conditions.   
SHR: The SHR rat strain originated in Kyoto, Japan, from the cross of an outbred Wistar male 
rat, which exhibited spontaneously elevated BP, and a female with slightly elevated BP (47). 
Subsequent brother-sister mating was continued with selection for animals with systolic BP over 
150mmHg.  The inbred strain was subsequently established in the US in the late 1960’s after 20 
generations of inbreeding at NIH (48) and spontaneously develops hypertension as adult animals. 
The SHR is widely used in different studies as a rat model of primary or essential hypertension. 
This strain, or substrains such as the Stroke-Prone SHR (49, 50), has proven useful in studies of 
stroke, vascular function, autonomic regulation, renal function, therapeutic interventions, and the 
genetics of essentialprimary hypertension.   
Dahl Salt-Sensitive Rats: DSS rats were developed by Lewis Dahl, who observed the 
beneficial effects of low sodium-containing diets in the 1950’s (51), and examined the influence 
of different salt diets on BP in outbred Sprague-Dawley (SD) rats.  Selective breeding of those 
rats fed high salt that developed hypertension led to the inbred DSS rats, which are often used in 
experiments examining the kidney, vasculature, and genetics in hypertension (51). Selective 
breeding of rats resistant to salt-sensitive hypertension led to the inbred Dahl salt resistant rats.  
Fawn Hooded Hypertensive Rat: The FHH model was derived by inbreeding the outbred 
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fawn-hooded (or fawn-headed) rat originally characterized for its bleeding disorder (52). The 
outbred rats were demonstrated to have an elevated mean arterial pressure in comparison to 
Wistar rats and were subsequently inbred by Provoost to produce two strains designated the 
hypertensive FHH and the normotensive fawn-hooded (also known as FHL) rat (53).  The FHH 
has been useful to address the genetics of hypertension and chronic kidney disease.  
Milan Hypertensive Strain: The MHS rats were derived from Wistar rats observed to have 
elevated BP (54, 55); the rats were inbred for multiple generations to establish a strain that 
spontaneously develops hypertension soon after weaning and plateaus at 7-8 weeks of age. MHS 
rats have been used to study essentialprimary hypertension.  The Milan Normotensive Strain has 
also recently proved useful for investigating genetic mechanisms mediating impaired myogenic 
responses and susceptibility to development of proteinuria and renal injury (56). 
Lyon Hypertensive Rats: In the late 1960’s, a group in France selected outbred SD rats for 
elevated, normal, or decreased BP, and that were subsequently inbred for multiple generations 
into strains with low, normal, or high BP (57, 58).  A separation of BP between the strains is 
evident at a relatively early age (5 weeks), and is subsequently sustained. These strains have 
been used for renal, metabolic, autonomic, cardiac and genetic studies (59).     
Sabra Hypertensive Rats: SBH rats were originally derived from Sabra outbred rats by 
brother/sister mating and selection for high BP following unilateral nephrectomy and treatment 
with DOCA and dietary sodium chloride (60, 61).  A secondary round of inbreeding more 
recently re-derived the Sabra hypertension prone (SBH/y) and resistant (SBN/y) rat models, 
which are also sensitive or resistant to DOCA-salt treatment (62).  The SBH rats have therefore 
been useful for genetic studies examining environmental interactions on BP.  
Experimental Use And Considerations: The most distinct advantage of the rat genetic 
models of hypertension are the similarities of the BP/hypertension phenotypes to those observed 
in patients and the genetic basis of disease development that occurs in these animals.  In 
combination with the relatively low costs associated with maintenance of rat colonies, the ease of 
experimental studies, and their relatively rapid growth and reproductive rate, the genetic rat 
models have been popular for experimental studies of hypertension. 
Genetics of hypertension: The inbred genetic rats have served as useful model systems to 
identify BP quantitative trait loci (QTL), regions on the genome that contribute to the elevation 
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of BP.  With the development and application of polymorphic microsatellite markers to identify 
BP QTL, linkage-mapping approaches were extensively used to study inheritance of 
hypertension in rat models.  Subsequent studies to validate these QTL were performed through 
the generation of congenic or consomic strains (46, 63). The subsequent identification of genes 
within these QTL has been dependent upon complementary approaches including transcriptomic 
analyses, gene sequencing, and gene editing approaches.  Perhaps the ultimate question related to 
the use of rat genetic models is the applicability of findings to human hypertension.  
Encouragingly, comparative mapping strategies have identified overlap of QTL’s detected in rat 
and human linkage studies (64), indicating that findings in rat models of hypertension may be 
translatable to human disease. 
Phenotypes and mechanism of hypertension: In the past 10 years, a major technological 
breakthrough occurred with the use of gene-editing technology to manipulate the rat genome.  
The zinc finger nuclease methodology for gene manipulation, pioneered by Geurts and Jacob 
(65), has permitted assessment of function of genes identified in human association studies to be 
examined in animals with a hypertensive genetic background (45, 66).  This approach has 
permitted elucidation of the function of a number of genes that associate with hypertension in 
human genome-wide association studies (GWAS).  Of note, the functional importance of various 
gene products with previously unrecognized function in the regulation of BP (e.g., an adherens 
junction protein, immune signaling proteins, a secreted metalloproteinase) have been revealed 
through the use of this technology in genetically hypertensive rats.  Similar studies are also 
underway using the more recently developed methods of gene manipulation involving CRISPR-
Cas system based technologies. 
Considerations: Important considerations to take into account with the use of genetic rat 
models include the choice of the appropriate model for a particular research question, the need to 
ensure an appropriate genetic background of the experimental and control rats, and the 
requirement for a controlled environment.  It should be noted that the basic genetic architecture 
of the SHR, and of other inbred strains in which the animals are homozygous at virtually all loci, 
is quite different from the genetic architecture of humans. The various genetic rat strains can be 
used as models of slowly-developing primary hypertension (48, 67, 68), juvenile hypertension 
(69, 70), salt-induced hypertension (51), and hypertension associated with end-organ damage 
(56)various genetic rat strains can be used as models of slowly developing essential 
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hypertension, juvenile hypertension, salt-induced hypertension, and hypertension-associated with 
end-organ damage. However, understanding the genetic composition of the hypertensive strain 
and the choice of an appropriate control strain are important (66).  A direct comparison of two 
strains of commonly-used DSS rats demonstrated over 1.3 million different base pairs between 
the strains, and a significant difference in BP when the rats were fed a high salt diet (45).  
Genetic differences between control strains must also be considered. Kurtz and Morris (48) 
demonstrated that the Wistar Kyoto (WKY) rat, a common genetic control for SHR, had 
profound differences in phenotypes (growth rate and BP) when obtained from different 
commercial suppliers.  Moreover, all “control” strains are necessarily limited in the absence of a 
complete understanding of the genetic differences between the control and hypertensive strains. 
These examples emphasize the importance of careful identification of and consistent use of 
strains when performing experiments.  Equally important are environmental influences on 
phenotypes. In inbred DSS rats, a simple substitution of the sodium-independent components of 
the diet could profoundly alter the salt-sensitive hypertension and renal damage phenotype (71). 
In summary, genetic rat models have demonstrated great utility and provided exceptional 
insight into the genetics and pathophysiology of hypertension.  A researcher interested in 
employing such models should carefully consider the disease traits of the different strains and 
appropriate genetic controls, and pay careful attention to controlling the environment.     
Transgenic models of hypertension  
The construction of high density comparative genetic maps between mouse, rat and human 
(72) reinforces the similarities (as well as differences) between these species. The millennium 
genome project for hypertension (73) stated as its aim the identification of hypertension-
susceptibility genes and pathways by a systemic multiple candidate gene approach. Candidate 
genes identified as possible contributors by GWAS screening can be interrogated in animal 
models using transgenesis - the stable introduction of modifications into the genome.  
Gene addition, resulting in over-expression of a given gene of interest, was classically 
achieved by microinjection of DNA into the single-cell embryo and monitoring its subsequent 
expression and phenotypic effect in the mouse (74, 75), and subsequently in rats and other 
species. Alternatively, the using of bacterial artificial chromosomes (BACs), which incorporate 
100s of kilobases of DNA, human chromagranin variants have been analyzed in mouse models, 
for their ability to reduce the risk of hypertension (76, 77). Gene targeting, resulting in loss of 
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gene function, was also achieved initially in the mouse following the development of embryonic 
stem cells (ESC).  The gene-targeting construct is introduced by transfection or electroporation 
into ESC, and those cells that have been correctly targeted by homologous recombination, are 
selected and injected into blastocysts. The resultant chimaeras are then bred and their progeny 
screened for incorporation of the genetic modification.  
ESC technology led to the supremacy of the mouse for generating new animal modeling of 
human disease over the following 25 years. Many developments, improvements and refinements 
in gene targeting during this time allowed the researcher to introduce precise and ever more 
ingenious genetic changes (Table A). Gene expression cassettes may be targeted to safe havens 
such as the ROSA 26 locus (78, 79). Fluorescent reporters, expressed in place of the gene of 
interest, but under its endogenous promoter, highlight the tissue- or developmental-specific 
pattern of expression. In some cases knockout of a gene may prove to be embryonic lethal, 
because it contributes to a critical stage in development. By flanking key exons of the gene with 
loxP sites and crossing the transgenic animal with animals that express the enzyme Cre 
Recombinase in a tissue- or developmental-specific manner, the gene can be knocked out later in 
development. Alternatively, transgene expression may be driven by an inducible promoter, so 
that its expression is under the control of the researcher. 
Prior to 2008 gene knockout in the rat or rabbit relied upon random mutagenesis using N-
ethyl-N-nitosourea, transposon-based systems such as Sleeping beauty, or spermatagonial stem 
cell targeting. Following identification of the signaling pathways that control self-renewal and 
differentiation of ESC, it was discovered that incorporation of certain inhibitors in rat ESC 
growth medium was sufficient to maintain them in the self-renewal, pluripotent state (80, 81), 
and a variety of species are now targetable through the ESC route. Hence, all the techniques 
developed in mice are potentially applicable to other species, like APOE knockout in rabbit (82). 
More recently, generation of transgenic animals has been transformed by the introduction of 
gene editing technologies using sequence-specific nucleases. The first of these, Zinc Finger 
nuclease (ZFN) targeting, requires two ZFNs to bind upstream and downstream of the target site, 
eventuating in a double strand break at the target site. The cell repairs the break, but it often 
results in introduction of small deletions or insertions. If the target site is within an exon, then 
such changes may lead to missense or nonsense mutations, effectively knocking out the target 
gene (83). Alternatively, a single strand oligo or plasmid can be added to direct a desired 
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sequence alteration or insertion at the target site. Geurts et al (65, 84, 85) used ZFNs (and 
subsequently CRISPr Cas9) to systematically knockout a number of GWAS candidate 
cardiovascular disease-related genes (86) through the PhysGen Knockout program.  
Transcription activator-like effector nucleases (TALENs) are a second class of nucleases, 
which also bind up- and down-stream of the target site and require the close proximity of FokI 
monomers to introduce a double strand break. Unlike ZFNs, TALENs targeting a specific 
sequence can be readily constructed from libraries of domains, each of which recognizes one 
nucleotide, making them widely accessible and relatively cheap. Recently, TALENs were used 
to generate two Pde1a null mouse lines, which revealed a role for phosphodiesterase 1 in BP 
regulation in addition to renal pathogenesis (87). 
The third and most readily available nuclease class is the clustered regularly interspaced short 
palindromic repeat (CRISPr/Cas9) system derived from the bacterial immune system of 
Streptococcus pyogenes. Though the CRISPr/Cas9 system is susceptible to off-target events, it 
has proved its worth in generating knockout models in a wide range of species. Of note is the 
recent CRISPR/Cas9 targeted knockout and subsequent knock-in of a 19bp indel polymorphism 
in a rat long non-coding RNA (Rffl-inc1). (88). Recent advances in CRISPR technology include 
generation of Cas9 derivatives with increased specificity (89, 90) and altered PAM recognition 
sequences (91) and development of other CRISPRs from alternative bacterial sources (92). The 
versatility of nucleases extends to the generation of large-scale deletions (93) and insertions (94), 
which allows for the humanization of animal models.  
Gene reduction or knockout has also been achieved using siRNAs. To prevent rapid 
degradation in vivo, miRNA mimics or anti-miR oligonucleotides require chemical 
modifications such as locked nucleic acid (LNA) modifications. LNA-modified anti-miRs 
proved to be effective in targeting miR-29b, which affects collagen gene expression in the renal 
medulla in DSS rats (95). Genetic modification can be achieved using recombinant lentiviral or 
adeno-associated viral-mediated delivery. Adverse reactions to the delivery vehicle need to be 
addressed, in addition to target specificity and cellular uptake (96). 
Cell ablation is a transgenic technique with numerous potential applications. Classically, 
diphtheria toxin A was used to achieve cell ablation (97). More recently, introduction of the 
nitro-reductase gene, together with pharmacological treatment with a pro-drug, Metronidazole or 
KillerRed, a far-red fluorescent protein, which is phototoxic to the cell on exposure to 
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appropriate laser light, have been used (98). Optogenetic cell ablation can be tightly controlled 
both spatially and temporally, allowing single cells to be ablated (99).  
The application of transgenesis to hypertension research 
The utilities of a transgenic model for investing the role of a specific gene in hypertension 
might include: 1) elucidating its basic function; 2) mechanistic understanding of its involvement 
in a particular pathway; 3) determining its contribution to essentialprimary hypertension; and 4) 
faithfully modeling the etiology of human hypertension, with a view toward identifying new 
therapeutic targets and drug treatments. 
Many candidate genes for human hypertension identified by GWAS have been individually 
found to make only small contributions to BP (<1mm Hg), suggesting that there are no common 
gene variants with major effects to promote essentialprimary hypertension (100-102). Though 
considerable basic knowledge regarding the complexities of homeostatic BP control has been 
gleaned from these studies, the lack of clinically relevant therapeutic targets emerging from this 
work is disappointing. Recently, a SNP in the third intron of the PHACTR1 gene, identified 
through GWAS studies, has been shown to enhance endothelin-1 expression in the vasculature 
(103). This is an example of a common non-coding variant contributing to vascular disease and 
hypertension. Similarly, Ji et al (104) found that rare gene variants in 3 genes, Na+-K+-2Cl- 
cotransporter [NKCC]2, ROMK and NCC, causing rare Mendelian syndromes with recessive 
inheritance, are surprisingly common, with 1 in 64 subjects in the Framingham Heart Study 
cohort carrying such a mutation (104). Since such rare variants cannot be detected by GWAS, 
this suggests that whole genome sequencing may be a more fruitful source of rare gene variants 
or epigenetic modifications that potentially contribute to individual propensity for hypertension. 
Relevant transgenic models might then be designed to confirm the effect of such variants on BP, 
and provide a valuable test-bed for therapeutic development. While the clinical relevance of a 
particular model is an important consideration, advancing understanding of basic mechanisms of 
hypertension is also of value and not incompatible with long-term translational goals.  
With the abundance of gene targeting tools particularly for the mouse, substantial basic 
understanding of rare Mendelian disorders associated with altered BP and renal sodium handling 
has been gained.  A mouse model of Liddle’s syndrome (2) containing a gain-of-function stop 
codon in -ENaC (reflecting the human mutation) exhibits normal BP unless placed on a high 
salt diet, when mice develop hypertension and hypokalemia. The hypervolemia suggested by 
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increased sodium reabsorption and low aldosterone on normal salt diet, together with salt-
sensitivity, replicates the human syndrome. The basic mechanisms of positive modulators of 
ENaC trafficking or expression, such as Sgk1, and Af17 and negative modifiers such as Nedd4-2 
have all been revealed with respective animal knockout models.  
Mice lacking NKCC2, which models Bartter syndrome, die from dehydration prior to 
weaning because of uncompensated polyuria (105). Bartter syndrome can also be modeled by 
knockout of ROMK (106) with animals exhibiting hypotension. NCC knockout, despite 
recapitulating features of Gitelman’s syndrome such as hypocalciuria, causes no reduction in BP 
unless the animals are put on a low salt diet (107). Renal knockout of Nedd4-2 (108) leads to 
salt-sensitive hypertension with increased NCC phosphorylation. NCC is also activated in 
Gordon’s syndrome through mutations in WNK4 (109), leading to hypertension and 
hyperkalemia. 
Rare conditions such as the syndrome of apparent mineralocorticoid excess, where 
hydroxysteroid dehydrogenase (Hsd)11b2 deficiency allows the mineralocorticoid receptor to be 
activated illicitly by glucocorticoids, have been modeled in both mouse (110-112) and rat (83) 
models. The global mouse knockout (112) replicates the human syndrome with hypertension and 
hypokalemia, and heterozygous animals exhibit salt-sensitivity (110). Recently, kidney-specific 
knockout of mouse Hsd11b2 was found to be sufficient to cause salt-sensitive hypertension 
attributed to ENaC and NCC activation (111). 
Renin knockout in both mouse (113, 114) and rat (115), results in significant hypotension. 
Knockout of the duplicated renin gene, Ren2, has no effect on BP in the mouse (114), but its 
over-expression in the SD rat leads to extreme hypertension (116). Subsequent crossing of the 
transgene onto inbred strains of rat that are susceptible (F344) or resistant (Lewis) to malignant 
hypertension, allowed identification of angiotensin converting enzyme as a modifier of end 
organ damage (117). The model has been improved further by placing expression of the mouse 
renin gene under an inducible (Cyp1a1) promoter (118). The timing and severity of hypertension 
in the Cyp1a1(Ren2) transgenic rat is thus under the control of the researcher. 
The action of AngII in the proximal tubule was determined in Ang receptor (AT1a)-deficient 
mice. Kidney expression of AT1a is necessary for AngII dependent hypertension, and specific 
removal (119, 120) or overexpression (120) in proximal tubules causes hypo- or hypertension, 
respectively, on normal salt diet. Meanwhile, animals lacking all three Ang II receptors reveal 
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that AngII controls BP by acting solely through these receptors (121). Humanization of both rats 
and mice with human renin and Ang genes (122, 123) has been useful for establishing species 
specificity of the RAAS, but more importantly such transgenics are useful for investigating the 
function of different haplotypes and species-specific RAAS inhibition. 
Conditional knockouts have been used to investigate the roles of endothelin-1 (ET1) and its 
receptor, ETA. Specific knockout of ET-1 in the collecting duct causes hypertension and sodium 
retention (124), while knockout of the ETA receptor in collecting duct prevents receptor 
antagonist related fluid retention (125). 
Gene knockdown is a potential therapeutic strategy. When adenovirus was used to direct anti-
miR against the AT1a receptor to the paraventricular nucleus of SHR, hypertension was 
attenuated (126). Likewise, siRNA against Nox2 or Nox4 has been used to attenuate BP in the 
aldosterone-salt mouse model (127). Transgenic technology has been used to ascertain the 
causative genes in multiple models of essentialprimary and salt-sensitive hypertension. For 
example, knocking out either NADPH oxidase 4 (Nox4) or the subunit, p67phox on the Dahl salt-
sensitive background significantly ameliorates both salt-sensitivity and albuminuria (128, 129).  
An extensive list of transgenic models that exhibit salt-sensitive hypertension is given in a recent 
AHA review (130). 
The size of the mouse can sometimes preclude its use in studies where substantial or multiple 
sampling is required. Though surgical instrumentation is routine (e.g. telemetric devices), there 
may be time constraints where, for example, battery life is limiting. Historically, the rat has been 
the model of choice in the pharmaceutical industry, so there is a wealth of physiological 
knowledge associated with this species (131). With development of protocols for ESC isolation 
and gene editing, rats, rabbits, and larger animals are now more likely to be considered as useful 
genetic model systems. With the rapidly expanding range of tissue and spatio-temporal controls 
that can be placed on the gene(s) of interest, and the possibility for multiple targeting or 
humanization, animal models can now be designed to answer ever more complex questions 
relating to human disease. 
There are caveats to the use of transgenic modeling, and these must be considered on a case–
by-case basis. Vector sequences may cause anomalous expression of a reporter, as reported in the 
vasculature of fli1:EGFP zebrafish (132). The pharmacological profile of the mouse and the rat 
may differ from that of the human, exemplified by the TRPA1 channel (133). Homologues to 
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human genes may be absent in animal models, or vice-versa. Finally, there may also be species-
specific differences in genetic mechanisms of disease progression or end-organ damage (134).  
The optically clear zebrafish has been very successful in informing basic understanding of 
organ development or function (135, 136). The advantage of ex-vivo development, together with 
optical clarity, facilitates the use of unparalleled optical and imaging techniques such as SPIM, 
optogenetics and optical ablation techniques. Whilst a relatively new species in cardiovascular 
science, the use of Zebrafish for studies of heart development and function and the cardio-renal 
axis combined with its facile genetic tractability and utility for high throughput screening of 
drugs and small molecules position it as a likely important species in future translational studies. 
In summary, transgenic technology affords a great deal of scope for generation of informative 
animal models, from identification of gene function to humanization. SNPs, suspected of being 
disease-related, can be investigated in vivo and potential therapeutic strategies tested. Also, with 
the latest developments in stem cell technology and genome editing, the choice of species is no 
longer limited to small rodents. 
Large animal genetic models  
Large animal models of spontaneous hypertension have been recognized and developed over 
the past 50 years.  Spontaneous (or primary) elevation of BP has been reported in a variety of 
large animal species including chickens, turkeys (137), rabbits (138), swine (139), dogs (140) 
and nonhuman primates (141).  In the avian species, elevated BP likely does not represent true 
“hypertension”, since BP differences are characteristic of comparisons with other species rather 
than intra-species variation. Other large animal models show intra-species variation in BP by 
individuals, indicative of hypertension and similar to that observed in humans.  Those species all 
exhibit clear genetic correlates among individuals with strong degrees of heritability.  Similar to 
the SHR, selective breeding of New Zealand and Dutch white rabbits generated one of the 
earliest large animal models of hypertension (138). Hypertensive animals tended to exhibit 
varying degrees of renal pathologies, possibly reflecting cause and/or a consequence of the 
hypertension. 
There are large animal models of spontaneous hypertension in dogs and swine exhibiting 
significant elevation in BP that is spontaneous and may be expanded by selective breeding.  
Interestingly, both dog (140, 142) and pig (139) models of spontaneous hypertension also have 
LVH, one of the most common cardiovascular complications of human hypertension portending 
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significant risk for morbidity and mortality. The canine model was derived from diagnosed 
essential primary hypertension in a female Siberian husky selectively bred over a 5-year period 
to normotensive males.  The offspring produced a colony of hypertensive animals with dominant 
heritability. Similar to the rabbit model, subsets of Guizhou mini-pigs and Sichuan domestic pigs 
exhibit renal disease with mild renal fibrosis, which may be partly responsible for hypertension 
(139).  In this spontaneous model of systemic hypertension, bilateral renal denervation 
normalized BP (143). The swine model also demonstrates spontaneous hypertension, due to a 
neurogenic mechanism potentially related to increased renal sympathetic outflow. Yet, unlike 
non-human primate models, mini-pigs do not typically have elevated heart rates. 
A nonhuman primate model of systemic hypertension was first reported in a small number of 
individual African Green Monkeys or vervets (144).  These findings have recently been 
extensively expanded through phenotyping of nearly 400 animals by forearm plethysmography 
(141). In this model, the mechanism is likely to be neurological in origin based upon the direct 
correlation between BP to elevated heart rate.  Although RAAS components were unaltered, 
these monkeys developed significant renal pathology in glomeruli and small vessels, resembling 
humans with essentialprimary hypertension.  Since the vervet genome has now been fully 
sequenced and a basic annotation published (145), defining the genomic mechanisms underlying 
the development of spontaneous hypertension may be possible.  Accordingly, this nonhuman 
primate model may have substantial utility for translational research on the genetic basis of 
human essentialprimary hypertension. 
PLATFORMS OF EXPERIMENTAL HYPERTENSION: INDUCED  
Renovascular  
The pioneering work by Goldblatt (37) and later Page (146) in the 1930s planted the seed for 
the development of surgically induced models of hypertension and opened a new chapter for 
hypertension research. Their work positioned the kidney and renal arteries on the complex map 
of the pathophysiology of hypertension and disclosed the unique relationship between the kidney 
and BP control that also propelled the development of various therapeutic interventions. Surgical 
induction of hypertension by reducing blood flow in the suprarenal aorta or main renal arteries 
with and without removal of renal mass, inducing compression of the renal parenchyma, subtotal 
nephrectomy, or sinoaortic baroreceptor denervation, are applicable to both small and large 
animal models with similar outcomes, underscoring pathophysiological mechanisms of 
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hypertension that likely are conserved across species.  
A common pathophysiological feature shared by models of renovascular hypertension is the 
driver of hypertension and target organ damage:  a reduction of blood flow to the kidneys 
resulting in decreased perfusion pressure activating the RAAS, leading to vasoconstriction, and 
salt/water retention, with systemic hypertension developing in a matter of days. Systemic 
hypertension induces progressive endothelial dysfunction, stretch, and organ damage, whereas 
chronic reduction of blood flow to the kidneys leads to tissue ischemia and subsequent release of 
hypoxia-activated factors and oxidative stress that activate inflammation. These processes in turn 
induce microvascular remodeling, fibrosis, and loss of renal function, which likely play a dual 
role by both maintaining hypertension and promoting target organ injury.  
Alternative approaches to surgically-induced hypertension, although less widely used, include 
direct damage of the renal parenchyma through compression (147), renal micro-embolization 
(148), and ureteral obstruction (149, 150), which often also activate the RAAS and elicit 
inflammation, renal fibrosis, and subsequent loss of renal function. A potential limitation of these 
approaches is a difficulty in controlling the degree of renal damage, and thus the development 
and severity of hypertension is less predictable. Another potential limitation is clinical relevance, 
since hypertension caused by parenchymal compression is infrequent in humans. Nevertheless, 
hypertension can be observed in humans with renal masses, such as subcapsular hematomas, 
tumors. Parenchymal compression has also been implicated in development of hypertension 
associated with obesity (151), thus potentially conferring significance for these surgical models 
of hypertension. 
Summary: Recommendations for using animal models of renovascular hypertension 
Although reduction of blood flow to the kidneys or induction of parenchymal injury represent 
less than 10% of the cases of clinical hypertension, target organ injury develops in a similar 
pattern to essentialprimary hypertension. Yet, models of secondary hypertension might be more 
suitable for assessing target organ injury and developing therapeutic interventions than for 
understanding the pathogenesis of human essentialprimary hypertension. Furthermore, the 
prominent involvement of the RAAS in many of these models may distinguish secondary 
hypertension from some forms of low-renin hypertension.  
Large animal models of renovascular hypertension may have several advantages beyond their 
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anatomical, physiological, and pathophysiological similarities to humans. For example, they may 
be more amenable than rodents for studies in chronic stable hypertension, allowing longitudinal 
quantification of relevant hemodynamic and biochemical parameters that characterize the 
progression of hypertension, target organ injury, and response to therapeutic interventions in a 
translational fashion (152). On the other hand, targeted interventions to resolve the vascular 
occlusion (153-157) are now feasible in both small and large animal models. Thus, both types of 
models might be used to tease out the driving force initiating hypertension, studying the potential 
for reversibility of target organ injury, and identifying mechanisms of organ damage that may be 
independent from hypertension. 
The ability to induce renovascular hypertension in genetically modified rodents offers unique 
opportunities for in-depth elucidation of pathophysiological mechanisms, opening the possibility 
for a more comprehensive understanding of the consequences of hypertension. Finally, both 
large and small animal models of renovascular hypertension offer the possibility of imposing 
other comorbidities, such as metabolic derangements, and determining their contributions to 
target organ damage (40, 158, 159) thereby realistically mimicking the clinical population of 
elderly hypertensive patients in which multiple cardiovascular risk factors often coexist. 
Angiotensin II-Dependent Hypertension 
The RAAS plays a fundamental role in normal sodium and water homeostasis. Accordingly, 
one of the most widely used pre-clinical models of hypertension, particularly in rodents, is 
chronic subcutaneous infusion of Ang II. The utility of this model accrues in part from 
resembling some forms of human hypertension.  The RAAS is broadly activated in human 
essentialprimary hypertension, and the level of BP elevation achieved with commonly used 
doses of Ang II in mice is on par with that seen in uncontrolled, Stage II hypertension. After 4 
weeks of chronic Ang II infusion in susceptible rodent strains, target organ damage is quite 
similar to that seen in human patients with sustained elevations in BP, including cardiac 
hypertrophy, vascular remodeling, and chronic kidney disease (160-163). Nevertheless, because 
the renal vasoconstriction attributable to Ang II can induce ischemia, particularly at higher doses, 
chronic Ang II infusion more closely models the renal injury that accrues from chronic renal 
ischemia in human hypertension rather than from barotrauma (164). 
 The Ang II infusion model was employed in early dog studies that characterized the 
functions of the RAAS (165, 166), but was adapted for chronic subcutaneous infusion in rodents. 
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Among rodents, rats develop target organ injury in response to Ang II more readily than mice 
and can more easily be surgically implemented with BP monitoring devices. On the other hand, 
mice breed more quickly, have a rapid onset of hypertension, and are amenable to gene targeting 
even within selected cell lineages. Among mouse strains, C57LB/6 mice are more resistant to 
renal injury and are not salt-sensitive, making this strain ideal for investigating RAAS-dependent 
hypertension in the absence of these 2 conditions (167, 168). By contrast, 129SVE mice are salt- 
sensitive, more susceptible to kidney injury, and manifest greater levels of BP elevation at 
similar AngII doses relative to C57BL/6(169). Mice from the FVB strain develop marked injury 
in several compartments within the kidney during Ang II infusion, particularly when combined 
with unilateral nephrectomy (170). Thus, the choices of species and strain are key considerations 
when designing experiments employing chronic Ang II infusion. 
In mouse studies, several doses of Ang II have been employed to induce and analyze 
hypertension of different severities. The “slow pressor” dose of 400ng/kg/min Ang II may mimic 
the gradual onset of hypertension in humans with essentialprimary hypertension (171). The 
intermediate dose of 490-500 ng/kg/min is the most widely used in recent years (161). A higher 
dose of 1000ng/kg/min Ang II was used to dissect the functions of AT1 receptors in distinct 
tissue pools during hypertension, and in conjunction with other modifications can provoke 
measurable renal damage in susceptible strains (162). Even higher doses are employed, albeit 
less commonly, to provoke cardiac fibrosis (172). Notably, these doses far exceed Ang II levels 
observed naturally in hypertensive humans. 
 The duration of infusion can be adjusted based on the cardiovascular control center 
studied. Acute BP effects of Ang II can be appreciated within seconds to minutes (173), whereas 
with chronic subcutaneous infusions of ≥ 500 ng/kg/min Ang II, increases in BP emerge within 
the first 24 hours (160). Vascular remodeling due to Ang II is evident within 2 weeks (161), and 
cardiac hypertrophy at 2-4 weeks (160, 174). Renal injury is reproducible at 4 weeks on 
susceptible strains (162, 175), but far more robust after 8 weeks (170). Thus, investigators should 
titrate the Ang II dose and study duration based the experimental question. 
The current state-of-the-art methodology for measuring BPs during chronic Ang II infusion is 
radiotelemetry (176). Using the older method of tail-cuff plethysmography the level of 
vasoconstriction with higher dose Ang II is so profound (164, 168), that extrapolating BP from 
blood flow velocity through the tail circulation may be misleading. Radiotelemetry also permits 
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accurate measurement of heart rate and arrhythmias.  
A few modifications to murine Ang II infusion can enhance its applicability to study injury 
and salt sensitivity. Unilateral nephrectomy, high salt diet, and/or an extended infusion period (8 
weeks) can yield more robust renal damage in mice (162, 170). As Ang II promotes sodium 
retention, a low salt diet can be added to chronic Ang II to understand the extent to which the BP 
elevation seen during Ang II accrues from its capacity to promote sodium retention (163).  
Summary and Future Considerations. While an aggressive pharmacological challenge to 
induce hypertension has obvious limitations, in several circumstances chronic Ang II infusion 
offers distinct advantages. First, it is the most direct approach for investigating the in vivo 
actions of angiotensin receptors and their downstream signaling cascades. Second, pairing 
chronic subcutaneous Ang II infusions with acute IV infusions allows a comprehensive profile of 
a protein’s vascular and renal functions during RAAS activation. Third, the model is 
reproducible across species. Finally, chronic Ang II infusion engages all the cardiovascular 
control centers in pathogenesis, allowing in vivo assessment of interactions between sympathetic 
and immune activation, systemic and renal vasoconstriction, and renal sodium transport. Thus, 
chronic Ang II infusion remains a useful tool to dissect coordinated contributions of multiple 
cardiovascular control centers in hypertension. 
Mineralocorticoid-Salt hypertension  
Administration of mineralocorticoids together with a high salt diet can induce hypertension in 
both large and small animals. In animals given a high salt-intake, administration of 
deoxycorticosterone (DOC), usually in the form of deoxycorticosterone acetate (DOCA), has 
been the most widely used approach for inducing mineralocorticoid-salt hypertension.  
Deoxycorticosterone DOC appears to have both glucocorticoid and mineralocorticoid properties, 
but its tendency to cause sodium retention appears central to the DOCA-salt model. Its 
mineralocorticoid potency, however, is less than that of aldosterone itself.  While elevated levels 
of deoxycorticosterone DOC can contribute to some rare human forms of hypertension, the most 
common human form of mineralocorticoid-dependent hypertension involves hyperaldosteronism.  
Thus, the development of animal models of hyperaldosteronism is a subject of considerable 
scientific interest (177). Recently, for example, a mouse model of aldosterone-salt hypertension 
was developed by transgenically expressing the human gene for aldosterone synthase under 
control of the human promoter for the gene encoding 11β hydroxylase (178).  
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Early studies showed that the effects of mineralocorticoids like DOCA were greatly enhanced 
in animals ‘sensitized’ to its actions by a high salt intake (typically 0.6-1% NaCl in drinking 
water) and often by uninephrectomy (179).  While initial studies emphasized the need for 
extremely high DOCA doses, lower doses reproducibly induce hypertension; doses typically 
currently range from 20-50 mg/kg (in rats) (180). Notably, using saline drinking solution without 
access to free water imposes a non-physiological stress on the animals that may affect the results; 
further, the models often become hypokalemic, and some investigators have therefore 
supplemented potassium.  Although rats are most commonly used for this model, it has been 
employed successfully using many different species, including mice, dogs, sheep, and pigs.  The 
model manifests low plasma renin activity (and low circulating AngII), so it bears some 
similarity to a common form of primary human hypertension, low renin hypertension. 
 
The DOCA-salt model appears to have volume-dependent, vascular, and neurogenic 
components.  Mineralocorticoids, dietary salt loading, and uninephrectomy would each be 
expected to promote increases in extracellular fluid volume, and it is thus not surprising that salt 
and water balances can be positive, especially early in the course of mineralocorticoid-salt 
administration.  Both plasma and extracellular fluid (ECF) volume are expanded (181), and these 
effects may appear to be sustained (182). However, the extent to which a high salt diet causes 
greater sodium retention and volume expansion in animals treated with deoxycorticosteroneDOC 
or aldosterone than in non-treated salt-loaded controls remains controversial (183).   While the 
classical model of mineralocorticoid-salt hypertension typically involves expansion of blood 
volume and ECF volume, hypertension may occur even when prominent volume expansion does 
not occur, as in the setting of a normal salt diet (182).  It should be noted that administration of 
mineralocorticoids to animals given a low salt diet usually induces little or no effect on BP.  
 
Shortly after DOCA-salt hypertension was described, it was recognized to have a substantial 
neurogenic component. DOCA-salt animals typically manifest sympathetic hyperactivity, 
perhaps resulting in part from increased plasma osmolality, which regulates lumbar sympathetic 
nerve activity. DOCA has been postulated to sensitize the brain to salt and osmolality (184). 
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Sympathetic hyperactivity increases vasoconstriction in both arterioles and in the venous 
circulation.  The importance of these effects has been supported by reports that lesions in the 
area postrema, anterolateral third ventricle, and paraventricular nucleus of the hypothalamus 
attenuate the hypertension (185). 
Although DOCA-salt hypertension is characterized by suppressed plasma renin activity, Ang 
II concentrations in the brain may actually increase, likely contributing to sympathetic activation 
and salt and water retention through effects on brain AT1 receptors (186). There is also evidence 
for a role of the prorenin receptor in these processes, as its blockade reduces BP in DOCA-salt 
animals (187).  In contrast, intrarenal RAAS does not appear to play a major role. The early 
studies of Selye and others indicated that DOCA-salt animals exhibited substantial systemic 
inflammation (188).  More recently, interest in the immune contribution to hypertension 
generally has reemerged. Harrison and colleagues have shown that T cells are important for the 
full effects of DOCA-salt to increase BP and to enhance superoxide production, clearly 
implicating a role for T cells in the model (161). 
In summary, the combination of mineralocorticoid treatment and  a high- salt intake, and 
sometimes with uninephrectomy, provides a reliable animal model that can develop severe 
hypertension with some features of human low-renin hypertension. Studies of such models might 
provide insight into the salutary effects of mineralocorticoid receptor blockade in the setting of 
resistant hypertension, even in patients without frank hyperaldosteronism. Thus, the 
mineralocorticoid-salt models may have broad applicability to those hypertensive patients in 
whom controlling BP presents a challenge. Such models could also have value for understanding 
why cardiovascular risk may be higher in humans with primary aldosteronism than in individuals 
with similar BP levels and hypertension of unknown etiology, 
Renoprival Hypertension  
The prevalence of hypertension among patients with kidney disease highlights the relevance 
of renoprival models to human hypertension, as more than 90% of patients with end-stage kidney 
disease are afflicted with hypertension. Pre-clinical renoprival models correspond precisely to 
the phenotype in the nephrology clinic that garners concern – a hypertensive patient who has 
developed chronic kidney disease. Another salient feature of renoprival models is the impairment 
in salt excretion that accrues from reduced nephron mass, allowing one to study the salt-
sensitivity that afflicts roughly half of human hypertensive patients. 
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 Remnant kidney models were developed in rats to explore the adaptive effects of renal 
mass reduction on the remaining nephrons (189). Accordingly, use of this model revealed the 
detrimental consequences of glomerular hyper-filtration, and the benefits of lowering glomerular 
pressure via inhibition of the RAAS. Extrapolation from these rat models provided some of the 
rationale for use of RAS blockers in patients with kidney disease and hypertension.  Infarction of 
2/3 of one rat kidney leads to BP elevation, whereas 2/3 nephrectomy together with total 
contralateral nephrectomy, the modern “subtotal nephrectomy” model, yields both hypertension 
and glomerulosclerosis.  In rats, 2/3 nephrectomy is typically performed on the left kidney and 
achieved via ligation of the posterior branch and the inferior segment of the renal artery (190). 
Adaptation to mice, typically as a “3/4” nephrectomy (1 nephrectomy plus resection of half the 
contralateral kidney), is technically challenging but has been executed with ligation of renal 
artery segments as in rats (191) or with direct excision of half a kidney using electrocautery or 
glue to achieve hemostasis (192). Hypertension develops universally in remnant kidney rats. By 
contrast, subtotal nephrectomy in mice induces hypertension in the 129SVE salt-sensitive strain 
but not in the C57BL/6 strain that is relatively salt-resistant (191, 193, 194). Hypertension and 
kidney disease progress more slowly and less severely in this model than in more aggressive 
pharmacological hypertension models, with studies reporting several months of data in rats and 
mice (193, 194). In rats, tailcuff plethysmography may be sufficient to detect a BP rise, but given 
the variability of responses in mice, radiotelemetry is recommended for BP monitoring in mice. 
Summary and Future Considerations. In the future, subtotal nephrectomy will likely remain a 
useful model of hypertension relevant to patients with advanced and progressive CKD. The salt 
sensitivity in the remnant kidney model seen with rats or 129SVE mice enhances its relevance to 
human subpopulations, such as African Americans, who are prone to salt sensitivity. 
Abnormalities in cardiac morphology and function such as LVH and altered diastolic relaxation 
seen with subtotal nephrectomy will provide a timely model of cardiorenal syndrome (190, 192). 
The glomerulosclerosis seen particularly in the rat model mimics the secondary focal segmental 
glomerulosclerosis that develops after several years of uncontrolled hypertension. The gradual 
increase in BP in this model emulates the BP trajectory seen in human essentialprimary 
hypertension more smoothly than abrupt induction of hypertension via pharmacologic 
perturbations. Nevertheless, hybrid models of renal mass reduction are now being used to 
enhance injury and/or shorten the time required for readouts.  For example, when vigorous 
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RAAS activation is needed, unilateral nephrectomy combined with Ang II infusion yields robust 
glomerular and tubular damage after 8 weeks, or after 4 weeks when a high salt diet is 
administered (162, 170). Alternatively, Ang II infusion combined with true subtotal nephrectomy 
in salt-resistant mouse strains like C57BL/6 can overcome resistance to hypertension in these 
strains (194). Thus, at institutions with skilled surgical personnel, the remnant kidney model 
alone or in combination with other approaches will continue to yield data relevant to human 
patients with hypertension and CKD. 
Nitric oxide system  
Nitric oxide (NO) is catalysed by endothelial nitric oxide synthase (eNOS) and its local 
release occurs on a continual basis thereby modulating effects of local and systemic 
vasoconstrictors and fine-tuning of BP and organ blood flow. Based on the premise that NO 
inhibition would lead to predominance of vasoconstrictors and consequent increase in BP, 
researchers began to explore the possibility that NOS inhibition would cause hypertension in 
animal models. In 1990, Gardiner et al showed that acute treatment of Brattelboro rats with NG-
monomethyl-L-arginine (L-NMMA), a methyl derivative of arginine and NOS inhibitor, caused 
an increase in BP (195). Ribeiro followed up on these studies and showed that chronic treatment 
of Wistar rats with the NO inhibitor, Nω-nitro-L-arginine (L-NAME), a nitro derivative of L-
arginine, increased systolic BP by over 60 mmHg (196). L-NAME-treated rats also show renal 
vasoconstriction and hypoperfusion (195-197).  As the disease progresses, it is characterized by 
renal dysfunction, renal hypertensive microangiopathy, cardiac, vascular and renal fibrosis and 
features of malignant hypertension. These studies defined a new model of hypertension induced 
by chronic NO inhibition and provided the hypertension community with a robust experimental 
model of severe/malignant hypertension with evidence of target organ damage.  
The mechanisms underlying L-NAME-induced hypertension seem to involve processes 
beyond inhibition of endotheliumal-derived NO, because infusion of L-arginine, which activates 
eNOS to produce NO, does not completely reverse hypertension. Chronic inhibition of NO likely 
has impact on BP regulatory systems beyond direct effects on vasodilation and vascular tone. In 
particular, persistent inhibition of NO biosynthesis with L-NAME is associated with profound 
vasoconstriction, activation of the sympathetic nervous system and the RAAS, oxidative stress, 
kidney damage and structural alterations of the vascular wall. Since RAAS inhibitors fail to 
completely ameliorate L-NAME-induced hypertension, other humoral factors, such as 
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endothelin-1, have also been implicated (197).  
As with all experimental models of human disease there are strengths and limitations that 
need to be considered for the chronic NO inhibition model of hypertension. The strengths of this 
pharmacological model of hypertension include the relatively simple technical approach, the 
reproducibility of the model, the development of systemic hypertension, the robust nature of 
severe hypertension, evidence of target organ damage, and reversibility of hypertension with L-
arginine and various commonly used antihypertensive drugs (198). However, the mechanisms 
underlying L-NAME likely involve processes beyond NOS inhibition, and more importantly, the 
pathophysiological role of decreased NO biosynthesis in human hypertension remains unclear. 
Moreover, the BP increase in NO deficiency hypertension occurs rapidly, usually within hours of 
L-NAME or L-NMMA infusion, while the development of hypertension in humans occurs 
slowly and becomes established after many years. Hence, while the L-NAME/L-NMMA rat is an 
excellent model of hypertension-induced target organ damage mimicking many of the 
complications observed in human hypertension, it is probably not an appropriate model for 
essentialprimary hypertension, which has a slow onset that develops over the lifetime, and 
caution needs to be considered when extrapolating findings from this model to the clinic (199).  
On the other hand, superimposing the L-NAME model onto conventional diabetic mouse strains 
accelerates kidney injury, recapitulating many features of human diabetic nephropathy (200, 
201). 
Summary and future directions: What we have learned from the chronic NOS inhibition 
model is that NO is a critical factor involved in the physiological regulation of cardiovascular 
function and homeostasis and is a key regulatory molecule involved in multiple functions, 
including vascular tone, renal function, salt-volume homeostasis and renin secretion. As such, it 
is a potentially attractive therapeutic target. While organic nitrates have been used to treat angina 
since the 1800s, these compounds have a short half-life with little benefit in chronic 
hypertension. Hence, there is now growing interest in the antihypertensive effects of inorganic 
nitrates in the diet, and in the development of modulators of NO that are stable and that will 
deliver NO in a tissue-and site-specific manner. Animal models may be useful in understanding 
the therapeutic potential of NO modulation in human hypertension. 
Several additional forms of hypertension that may develop in animal models are less common 
and have not been described here. These include models of hypertension induced by infection, 
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heavy metals, stress (e.g., air jet, psychosocial, cold-induced, etc.), medications and herbal 
supplements (acetaminophen, NSAIDs, licorice, etc.), hypothyroidism, hyperparathyroidism, and 
others, which have been described elsewhere. 
OBESITY  
Overweight and obesity contributes to up to 75% of the risk for essentialprimary 
hypertension, and to most cases of treatment-resistant hypertension. While the physiological and 
molecular mechanisms of obesity-related hypertension remain unclear, sodium retention, RAAS 
activation, increased sympathetic activity, leptin resistance, and endothelial dysfunction have 
been implicated. Elucidating the mechanisms responsible for obesity-related hypertension may 
allow development of novel strategies for treating these patients. 
Overall, animal models that exhibit concomitant obesity and hypertension can be divided into 
2 distinct categories: models of obesity that spontaneously develop hypertension, and models of 
hypertension with superimposed obesity. Despite their different etiologies, both types of models 
allow exploring the role of obesity in the development and progression of hypertension. While 
models of primary obesity permit evaluating the mechanisms by which obesity predisposes to 
hypertension, models of hypertension enable studying how obesity alters its course.  
Several models of experimental obesity spontaneously develop hypertension as they gain 
body weight. Genetically induced obesity models that develop hypertension include the obese 
Zucker rat (OZR), ZSF1 rat, Wistar Fatty rat (WFR), and ob/ob mouse, which result from 
mutations that interfere with leptin signaling and transduction. These models are the most 
commonly used and offer the advantage of minimizing the impact of confounding factors, 
allowing mechanistic studies to investigate the role of specific genes in obesity-induced 
hypertension. Genetically induced obesity-hypertension can be also achieved in large animal 
models. For example, DNA transposition of D374Y gain-of-function cDNA of chimp proprotein 
convertase subtilisin/kexin type-9 is associated with elevated BP (202). However, coexisting 
obesity and hypertension result from the combination of genetic and environmental epigenetic 
factors. Thus, genetically induced obesity models may not fully address this need. 
Diets rich in saturated fats and refined carbohydrates induce weight gain and changes in body 
composition and adipose tissue cellularity both in rodents (203, 204) and several large animals, 
including dogs (205), rabbits (206), and pigs (207). The rat might be the optimal small animal 
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model for diet-induced hypertension, because of its size and the propensity to develop 
hypertension faster than mice. High-carbohydrate diets, alone or in combination with high-fat 
diets, have been shown to induce obesity, hypertension, hyperlipidemia, and glucose intolerance 
in several rat strains, including SD and Wistar rats within just 3 weeks (208, 209). However, 
C57BL/6 mice fed a high-fat/high-carbohydrate diet supplemented with NaCl may need as much 
as 3 months to develop hypertension (203). Unlike rodents, development of hypertension is 
relatively similar among large animals of obesity ranging from 5 weeks in the dog (210) to 12-16 
in the pig (207). Although a mixture of chow and added fat may be sufficient to develop obesity-
hypertension, purified-ingredient diets are the preferred choice, due to their low batch-to batch 
variability and lack of plant-derived phytochemicals, which may alter disease progression (211). 
Purified diets contain high levels of carbohydrates, which are indispensable to achieve several 
features of metabolic syndrome, and particularly hypertension. Pigs fed a high-fat diet alone are 
characterized by dyslipidemia and vascular dysfunction, but do not increase BP levels (212). 
Contrarily, feeding domestic pigs with a diet containing high levels of carbohydrates, fat, and 
cholesterol over 16 weeks induces spontaneous hypertension (207). Although high-fructose diets 
seems to be more effective in inducing metabolic syndrome compared to high-sucrose diets, diet-
induced increase in BP levels is comparable (213). 
Lastly, chemical agents (e.g., monosodium glutamate) primarily used to induce obesity may 
result in spontaneous hypertension (214). Yet, the association between obesity and hypertension 
in these models is often weak.  
In addition to models of primary obesity, models of concurrent, independently achieved 
hypertension are critical to answer the fundamental question of whether obesity exacerbates 
existing hypertension. For example, fat loading in DSS rats aggravated BP and salt-induced renal 
damage, preceded by body weight gain, visceral fat accumulation, and insulin resistance (215). 
Similarly, studies in Ossabaw pigs with coexisting obesity and renal artery stenosis demonstrated 
that obesity amplifies both renal and cardiac injury, yet BP levels remained unaltered (216, 217). 
These observations suggest that the primary mechanism implicated in the development of 
hypertension is an important determinant of the effect of obesity. While obesity exacerbates salt 
sensitivity of BP, the effect of hypertension may be dissociated from obesity in surgically 
induced hypertensive models.  
Alternatively, the impact of obesity on hypertension could be studied by genetic or dietary 
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manipulations. In the spontaneously hypertensive obese (Koletsky) rat, hypertension and obesity 
are induced by independent genetic mutations (218). Interestingly, BP levels are comparable to 
rats with salt-sensitive hypertension, suggesting that obesity induced by this mutation does not 
exacerbate genetically induced hypertension. Contrarily, DOCA-salt treatment of obese Zucker 
rats increases BP as fast as with 4 days (219). Therefore, these models are suitable to explore if 
obesity increases the sensitivity of animals to experimentally induced hypertension. Presumably, 
the involvement of the RAAS, oxidative stress, or other mechanisms, may dictate the sensitivity 
of the models to coexisting obesity and hypertension.   
The choice between small or large animal models of obesity-hypertension should consider 
several elements (see section). Specifically, large animal models of diet-induced obesity may 
require a long period of time to develop spontaneous hypertension, increasing experimental 
costs. In addition, body weight, length, and fat percentage may reach significant proportions, 
limiting animal mobility and increasing the risk for infections and surgical complications.     
SEX DIFFERENCES AND AGING IN HYPERTENSIVE SMALL ANIMAL MODELS 
Profound sex differences are an important feature of hypertension and cardiovascular diseases 
in humans. Similarly, sex differences in BP have been noted in most animals, including rodents, 
dogs, chickens, and rabbits (220, 221), but the mechanisms responsible for the sex differences in 
hypertension or BP control have mainly been studied in rodents (Table B). Almost without 
exception, young adult male rats have higher BP than females regardless of whether they are 
normotensive (SD) or hypertensive (SHR, DSS), just as in humans.  In normotensive SD rats, 
mean BP is lower in females than in males (222), possibly due to lower proximal sodium 
reabsorption and greater ability to excrete sodium (223). There are also greater pressor responses 
in males with DOCA-salt hypertension (224) and DSS rats (225).  In both mice and rats, 
normotensive males also develop higher BP in response to a “slow pressor” dose of Ang II (226, 
227).  The mechanisms responsible for the elevated BP or response to Ang II vary with the strain 
and genetics of the rodents. The kidney and perhaps the sex steroid milieu might be responsible 
for the sex differences in the Ang-II mediated hypertension. However, in general, radiotelemetry 
monitoring shows that the estrus cycle of the female does not affect daily BP markedly. 
Aging in humans is associated with an increase in BP. In hypertensive rat models, BP 
increases in females as they stop estrous cycling.  In SHR, BP is lower in females prior to 
stopping estrous cycling, and then increases progressively such that by 16 months of age, BP in 
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females is similar to or higher than males (228). In DSS rats on a low salt diet, aging in both 
males and females is also associated with increases in BP (229).  In many hypertensive rat 
models hypertension is mediated by different mechanisms for males and females. Contributions 
of hormones, sympathetic and renal nervous systems, immune system, metabolic syndrome 
effects, and oxidative stress, which are different between males and females, must be taken into 
account.  Thus, sex differences in BP control in animals are as complicated as in humans. 
Role of Sex steroids: The presence or absence of sex steroids is an important mediator of 
hypertension in many of the spontaneously hypertensive rodent models.  Castration of male 
SHR, DSS, and mREN2 models causes a reduction in BP, and ovariectomy increases BP in DS 
rats, on a high or low salt diet (229), and in mREN2 females (224).  In contrast, ovariectomy of 
SHR has no effect on their BP (225).  Exogenous androgens given chronically increase BP in 
female SD rats, a model of polycystic ovary syndrome (230). The mechanisms by which sex 
steroids can impact BP include stimulation of renal angiotensinogen synthesis by androgens, and 
estrogen-mediated stimulation of the vasodilator arm of the RAAS or decreased AT1 receptor 
synthesis.  Estradiol also increases expression of endothelial nitric oxide synthase. 
Sex and aging-related differences in mechanisms responsible for hypertension in young 
SHR  
In young male and female SHRs the mechanisms responsible for hypertension are different.  
For example, in young adult male SHR, the hypertension is mediated by androgens since 
castration reduces BP to similar levels as in females, and androgen supplementation restores the 
hypertension (231), whereas ovariectomy has no effect in females, suggesting that estrogens 
have no effect on BP in females. Removal of the renal nerves or adrenergic blockade normalizes 
BP in both male and female SHR (232).  Central melanocortin-4 receptor (MC4R) antagonism 
also reduces BP in young male SHR (233), but not young females (234), suggesting that 
sympathetic activation in males may be due to MC4R activation. Blockade of the RAAS with 
ACEI (231, 235) normalizes BP in both young male and female SHR. 
In young adult male and female SHR, removal of the renal nerves or adrenergic blockade 
normalizes BP (222), but the mechanism responsible is different for the sexes. Central blockade 
of the melanocortin-4 receptor (MC4R) reduces BP in males, (223), but not females. However, 
with aging, BP falls with renal denervation or adrenergic blockade, but both male and female 
remain hypertensive (223), implicating multiple mechanisms in the hypertension in aging SHR. 
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The role of oxidative stress in mediating hypertension in SHR is also sex-dependent, although 
females have similar or higher levels of oxidative stress markers.  Overall, antioxidants prevent 
development of hypertension in both sexes of SHR (236, 237), but once established, maintenance 
of hypertension is independent of oxidative stress in females, but not males. The NO system may 
also be more activated in young females than males SHR (238). Interestingly, 
tetrahydrobiopterin supplementation reduces BP in male SHR, but this is due to a concomitant 
reduction in androgen levels rather than protecting against eNOS uncoupling (239). Inhibition of 
20-HETE synthesis, either by non-specific arachidonic acid metabolism inhibitor or a specific -
hydroxylase inhibitor, reduces BP in male SHR (240), but not young females (230). Blockade of 
the RAAS reduces BP to similar levels in both male and female SHR when they are young (231), 
but becomes less efficacious with aging in females (235).  In addition, the endothelin and the 20-
HETE eicosanoid systems may contribute to hypertension in aging females.  
Sex differences in inflammation and the immune system also contribute to the hypertension 
(Table B).  Both male and female SHR have a depressor response to the lymphocyte inhibitor, 
mycophenolate mofetil, but the greater response was in females (241).  Females have more 
circulating CD3+, CD4+, and pro-inflammatory CD3+CD4+RORγ+ Th17 cells, whereas males 
have more immune-suppressive CD3+CD4+Foxp3+ T regulatory cells.  In the kidney, females 
had greater numbers of CD8+ and regulatory T cells infiltration, whereas males had greater 
CD4+ and Th17 cell infiltration. The role of T cells in mediating hypertension is emerging. For 
example, females show greater pressor response to Ang II after male-to-female T cell transfer, 
and males become less responsive after female to male T cell transfer. Future studies will be 
necessary to determine the role that T cells play in mediating essentialprimary hypertension in 
humans, in order to refine studies in animal models. 
Aging and sex differences in mechanisms responsible for hypertension   
As noted above, with aging and cessation of estrous cycling, BP increases in female SHR to 
levels similar to or higher than in males (228), despite the lack of effect of ovariectomy on BP in 
young females (231).  The mechanisms responsible for hypertension are also different by sex in 
aging SHR.  For example, while BP falls with renal denervation or adrenergic blockade, both 
aging males and females remain hypertensive (234), which does not occur in young animals, 
suggesting that other components contribute to the hypertension in aging SHR. Similarly, 
blockade of the RAAS reduces BP but becomes less efficacious with aging in females (235), but 
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normalizes BP in aging males as in young males.  While the endothelin system plays no role in 
mediating hypertension in young male or female SHR, with aging ETA receptor antagonism 
modestly reduces BP in females, but not males (230).  Blockade of 20-HETE synthesis fails to 
reduce BP in young female SHR, whereas 20-HETE synthesis inhibition reduces BP in old 
females (242), suggesting that unlike in young females, 20-HETE contributes to regulation of BP 
in old female SHR.    
In DSS rats, BP in females does increase with ovariectomy and decreases with estradiol 
supplements (229).  Interestingly, by 12 months of age, estradiol-supplemented ovariectomized 
DSS rats, ovariectomized DSS rats, and intact DSS rats have similar BP (229), suggesting that 
with aging changes occur in the estrogen receptors or intracellular signaling pathways that make 
the estradiol no longer able to attenuate the BP. 
Other comparisons for BP regulation in male and female DSS rats are not as comprehensive 
as in SHR and are thus not discussed further. 
Other mechanisms underlying sex differences in hypertension 
Sex differences in BP have been reported in most models of diet-induced obesity. Male 
C57Bl/6 mice on a 16-week high fat diet gained less weight than females, but developed 
hypertension (243). Male Obese Zucker rats have higher BP than females (244).  The 
mechanisms responsible for the sex differences in BP in these rodent models remain unclear.   
In large animal models, many studies have been performed in dogs, although the sex has not 
been often considered. Ang II given intra-cerebroventricularly to dogs caused a pressor and 
dipsogenic effect in male dogs but not females (245).  Male rabbits have higher BPs than 
females, but neither are salt sensitive (221).   
In summary, many rodent models show sex differences in the BP levels, and hypertensive 
mechanisms responsible for these are different. As shown in Table B, in general, in female 
animal models, the mechanisms responsible for hypertension are more multifaceted than in 
males, and these mechanisms tend to increase in number and significance with aging.  Therefore, 
investigators should be cognizant of and look for sex differences in BP, recognize that there may 
be sex differences in the mechanisms responsible for BP control, and recognize that there may be 
age-related differences in the mechanisms responsible for BP control as well. 
END-ORGAN DAMAGE  
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The impact of hypertension on human health occurs through damage to critical target organ 
systems including the brain, heart, kidneys and vasculature.  Investigations on target organ 
damage in many established rodent models of hypertension have revealed insights into 
mechanisms of BP-induced tissue injury. However, with the growing importance of co-
morbidities and aging in hypertension and its complications, studying aged animals and animals 
with induced co-morbidities, such as hyperglycemia, hyperlipidemia and obesity, would further 
increase the translational relevance of animal models of human hypertension. 
Vasculature: Vascular dysfunction and remodelling  
In hypertension, endothelial dysfunction is associated with may precede overt evidence of 
target organ damage, and has been demonstrated in peripheral, coronary, cerebral, renal and 
conduit vessels in experimental and clinical hypertension.  Molecular processes causing 
endothelial dysfunction include decreased endothelial NO production, increased bioavailability 
of reactive oxygen species, increased ET-1 and Ang II production, and immune mechanisms. 
Hypercontractility also contributes to high vascular tone in hypertension. Processes underlying 
this involve increased vascular smooth muscle cell contraction and reduced relaxation, mediated 
in large part through changes in intracellular calcium concentration and activation of RhoA-Rho 
kinase pathways.  
In addition to functional alterations, small and large arteries exhibit structural changes in 
hypertension, characterized by remodeling, fibrosis, and inflammation, processes that are 
amplified with aging in SHR (246). Resistance artery narrowing and large artery stiffening are 
not only target organ effects of high blood pressure, but these vascular changes contribute to the 
development of hypertension by increasing peripheral resistance and compromising arterial 
compliance.  
Structural remodeling of the vascular wall leads to reduced lumen diameter and thickening of 
the vascular media. Remodeling of small arteries may be the first manifestation of target organ 
damage in hypertension. In clinical studies, 100% of patients with stage 1 hypertension have small 
vessel remodeling whereas only 60% have endothelial dysfunction and 45% have left ventricular 
hypertrophy (247).  The concept of ‘vascular remodeling’ was first suggested in 1989 when pial 
arterioles from SHRSP were found to have significant structural alterations (248). Arterial 
remodeling is characteristically associated with increased wall thickness, of which two types are 
described: inward or outward, depending on whether the lumen diameter is reduced or increased 
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respectively. Remodeling is further classified into eutrophic, hypotrophic or hypertrophic 
depending on whether there is no change, reduced or increased vascular material (vascular smooth 
muscle cells, extracellular matrix) respectively (249, 250). Eutrophic inward remodeling is usually 
found in SHR and Ang II-induced hypertension, whereas hypertrophic remodeling is found in 
renovascular hypertension, salt-sensitive hypertension, aldosterone-induced hypertension and 
other forms of secondary hypertension (Table D). Different types of remodeling may occur in 
different vascular beds, for example in SHR, small resistance arteries exhibit eutrophic inward 
remodeling whereas conduit arteries undergo hypertrophic remodeling. Associated with structural 
alterations are mechanical changes that promote arterial stiffness, decreased elasticity and reduced 
distensibility, which further contribute to vascular target organ damage. 
In addition to functional alterations, vessels exhibit structural changes in hypertension, 
characterized by remodelling, fibrosis, and inflammation, processes that are amplified with aging 
in SHR (246). Structural alterations of the vascular wall lead to reduced lumen diameter and 
thickening of the vascular media. Associated with structural remodelling are mechanical changes 
that promote arterial stiffness and reduced distensibility.  
The most commonly used approaches to directly assess in experimental models of 
hypertension vascular function (endothelial function, vasoconstrictor and vasodilator properties), 
along with structure and mechanical properties, are is by myography (wire and pressure) 
myography. Wire myography allows ex vivo measurement of transverse isometric tension in an 
arterial segment in response to different factors, and assessing biochemical and molecular 
pathways and passive properties of the vessel (251). Pressure myography is used to assess small 
vessel function and structure under near physiological conditions of pressure and flow by 
digitally tracking diameter and flow in real time (252). Parameters studied assessed by pressure 
myography include media structure, wall stress, strain and myogenic tone, and allows evaluation 
of responses to increases in pressure, flow and pharmacological stimuli. The system can be 
linked to imaging equipmentsystems, for example to assess calcium transients. These approaches 
have been used extensively in various rodent models of hypertension, including L-NAME-rats, 
SHR, SHRSP, salt-sensitive rats, renovascular models, Ang II-induced hypertension and 
transgenic mice, and have contributed enormously to elucidating the vascular phenotype as a 
cause and target of hypertension.  
In addition to impaired endothelial function, hyper-reactivity and structural remodeling, 
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hypertension-induced vascular damage may involve rarefaction, which is characterized by a 
decrease in microvascular density. Rarefaction may be functional (vasoconstriction) or structural, 
and may contribute to 25% of peripheral resistance in experimental hypertension (249). 
Heart: Cardiac Fibrosis, Hypertrophy, and Hypertensive Heart disease.  
Cardiac injury is a major consequence of persistent, uncontrolled hypertension. Elevated BP 
culminates in myocardial strain resulting in LVH, an independent risk factor for cardiovascular 
mortality. Disruption in cardiac architecture with LVH is associated with aberrant electrical 
conduction leading to atrial or ventricular arrhythmias and sudden death. When the heart can no 
longer sustain normal function in the face of elevated afterload, persistent hypertension leads to 
diastolic and ultimately systolic heart failure. Accordingly, hypertension is a leading cause of 
congestive heart failure in humans.   
In many rodent models of hypertension, approximating human Stage 2 hypertension leads to 
LVH within 2-4 weeksBP elevation leads to LVH, measured by augmented heart-to-body-weight 
or heart-to-tibia-length ratios. Indeed, tThe level of BP measured by radiotelemetry correlates 
with the extent of cardiac hypertrophy (160), making heart weight a possible surrogate for 
hypertension where direct measurements are unavailable. Rodent echocardiography allows direct 
assessment of changes in cardiac filling patterns and left ventricular wall thickness. These 
detailed measurements allow discrimination between signaling pathways that favor physiological 
versus pathogenic cardiac hypertrophy.  
After one month, hypertensive cardiac injury in rodents is marked at the histologic level At 
the histologic level, hypertensive cardiac injury in rodents is marked by myocyte damage, mild 
perivascular fibrosis, and sparse mononuclear cell infiltrates (160), which nonetheless modulate 
cardiac injury during hypertension. At the molecular level, cardiac hypertrophy is characterized 
by recapitulation of fetal gene expression in experimental hypertension (253). Severe 
hypertension provides a model of cardiac fibrosis, which can be quantitated by 
immunohistochemistry and molecular signatures of cardiac scar formation. Scarring disrupts 
electrical conduction in the heart with consequent discrete dysrhythmias that can be captured and 
quantified with current radiotelemetry monitoring systems (254).  
Kidney: Renal Fibrosis and Hypertensive Kidney Failure 
Hypertension-induced renal damage (HIRD) comprises at least three patterns: benign 
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nephrosclerosis, malignant nephrosclerosis, and hypertension-accelerated kidney disease (255). 
Benign nephrosclerosis is characterized by arteriosclerosis, interstitial fibrosis, and global 
glomerulosclerosis.  The individual risk of end-stage kidney disease from benign nephrosclerosis 
is surprisingly small, but the net effect of benign hypertension is significant, because 
hypertension itself is so common.  In contrast, malignant hypertension, which itself is 
uncommon, typically leads to kidney damage, often associated with fibrinoid necrosis and 
thrombosis of small vessels and glomeruli. HIRD most commonly occurs in the setting of 
underlying kidney disease, in which hypertension accelerates progression, for instance of 
diabetic kidney disease.  
The three subtypes of HIRD have been replicated in animal models.  Rodent models like SHR 
develop kidney damage very slowly.  This appears to reflect preserved renal vascular 
autoregulation, with normal pressure-induced afferent vasoconstriction, preventing high arterial 
pressure from being transmitted to the glomerular capillaries (256). This model resembles benign 
hypertension in humans, in which the risk for hypertensive nephrosclerosis is low, and damage is 
restricted primarily to pre-capillary blood vessels and interstitium.  In contrast, when arterial 
pressure rises above a critical threshold, for example in stroke-prone SHR rats exposed to high 
salt intake, renal damage develops rapidly, with lesions characteristic of malignant hypertension 
(257). In this case, the pressure is above the autoregulatory range, and is therefore transmitted 
directly to the glomerulus.  This causes proteinuria and rapidly progressive renal dysfunction, 
resulting from glomerular damage.  These characteristic features of human malignant 
hypertension can also be observed in Ren2-transgenic rats. 
In the setting of underlying renal disease, the relationship between arterial pressure and 
kidney damage shifts, and BPs that do not normally lead to progressive damage do so. 
Mechanisms involved are controversial and depend on the models employed.  Many studies use 
5/6th nephrectomy (See under “Renoprival Hypertension”).  Kidney damage has been suggested 
to result from resulting dilation of the afferent arteriole, with efferent vasoconstriction, which 
together increase glomerular capillary pressure, independent of changes in arterial pressure.  In 
contrast, a surgical approach to reduce renal mass without generating hypertension showed that 
systemic hypertension is required for renal damage (258). Mouse strains vary in their 
susceptibility to kidney damage.  Rodent models of diabetic kidney disease, for example that 
induced by streptozotocin on a 129SvE background, have been used to demonstrate the impact of 
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superimposed hypertension on baseline kidney damage (259).  
Brain: Hypertensive Cerebral Damage 
Hypertension is a major risk factor for cerebrovascular diseases, such as stroke (ischemic and 
hemorrhagic) and vascular dementia, but also for neurodegenerative diseases, including 
Alzheimer’s disease (260). Hypertension has damaging effects on cerebral blood vessels, which 
have been implicated in its harmful effects on the brain. Lacking energy reserves, the brain is 
highly susceptible to alterations in blood supply, and hypertension can promote both acute and 
chronic ischemic brain injury (261). As in systemic arteries, hypertension accelerates 
atherosclerosis and induces stiffening, remodeling and hypertrophy in cerebral arteries. 
Distinctive alterations, similar to those observed in the kidney (lipohyalinosis), are observed in 
penetrating arterioles of the brainstem and basal ganglia. Functionally, hypertension alters 
myogenic tone and cerebrovascular autoregulation, induces endothelial dysfunction, impairs the 
ability of neural activity to increase cerebral blood flow (neurovascular coupling), and damages 
the blood-brain barrier. These structural and functional alterations promote vascular occlusions, 
leading to acute ischemic brain injury, and chronic vascular insufficiency causing white matter 
damage.  A major consequence of the hypertensive white matter damage is cognitive 
impairment. Indeed, hypertension is the major cause of cognitive impairment on vascular bases, 
the most common cause of dementia after Alzheimer’s disease (260). Executive dysfunction and 
psychomotor slowing are the typical cognitive deficits, but memory impairment, more 
characteristic of Alzheimer’s disease, can also occur in more advanced cases (260). In addition, 
hypertension induces rupture of cerebral microvessels causing intracerebral hemorrhage, 
typically in the basal ganglia, or bursting of aneurysmal dilatation in arteries at the base of the 
brain resulting in subarachnoid hemorrhage.  
Several animal models of hypertension have been used to investigate the effects of 
hypertension on the brain (Table C).  Although these models do not fully recapitulate the harmful 
effects of hypertension, they have provided valuable knowledge on the potential mechanisms 
underlying the susceptibility of the brain to hypertension.  Most of the models used for 
cerebrovascular research have been in rodents, although there have been studies in larger 
animals, mainly pigs and monkeys. As noted earlier, models based on administration of 
pharmacological agents have the advantage that the cause hypertension is known, and can be 
induced in a defined time frame and in transgenic animals, allowing studying early mechanisms 
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of disease at the molecular level, as well as cognitive dysfunction. A disadvantage is that that the 
hypertension is limited in time (usually weeks) and does not mimic the long-lasting impact on 
the brain of the human disease. Nevertheless, these models have been some of the most 
commonly used.  
Genetic models based on intercrossing and selecting for the hypertensive phenotype, e.g., 
SHR-SP, BPH2 mice, exhibit life-long hypertension and provide insight on the effects of 
hypertension on the brain, including cognitive dysfunction, over the life course. However, the 
precise cause of the hypertension remains unknown, raising the possibility that the 
cerebrovascular alterations are not attributable to hypertension, but to unrelated genetic factors. 
For example, the increased susceptibility to ischemic brain injury in SHR and SP-SHR could be 
related, in part, to an inherited vulnerability of neurons to excitotoxicity (262, 263). Some 
transgenic models have life-long hypertension with a known cause, e.g., mice overexpressing 
human angiotensinogen and renin (R+/A+) or lacking eNOS, and have been very useful to 
investigate the role of specific pathways and mediators in the effects of life-long hypertension on 
the brain.  
Some hypertension models that produce brain lesions (infarcts, hemorrhages, or white matter 
lesions) usually require the combination of pharmacological, dietary, genetic and/or surgical 
manipulations to enhance the effects of hypertension on the brain (Table C). While mimicking 
the neuropathological impact of hypertension, the time when lesions develop cannot be predicted 
and the location of the lesions is highly variable.  
Of particular interest are models in larger animals, such as pig and monkeys, in which brain 
size, gray-white matter ratio, vascular topology, cognitive testing, and cardiovascular function 
have greater translational relevance (264). Monkeys made hypertensive by aortic coarctation 
exhibit white matter lesions and microinfarcts and, like the pig model, lend themselves to more 
detailed assessment of cognitive endpoints (Table C). However, these models are expensive, not 
well suited to high throughput investigations, and less amenable to genetic manipulations.  
In summary, while investigations on target organ damage in animal models of human 
hypertension have focused mainly on vessels, the heart, and the kidney, there is a paucity of 
information on the brain effects in these models. This is particularly evident in renovascular 
hypertension and low-renin hypertension. Considering the devastating impact of hypertension on 
the brain and its vessels, and its pathogenic role in wide variety of brain diseases, there is a 
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strong rationale for expanding application of state-of-the-art cerebrovascular and neurovascular 
investigative tools to delve deeper into the mechanisms through which hypertension promotes 
neurovascular and neurodegenerative diseases.  
APPLICATIONS OF GENETICS AND SYSTEMS BIOLOGY TO ANIMAL MODELS 
Great insight has been gained from the genetic study of human hypertension. Studies of 
monogenic forms of hypertension have revealed the molecular basis of several related 
syndromes.  More recently, GWAS analyses uncovered common variants of modest effect as 
well as low-frequency variants that contribute to BP variation in patients. These studies provide 
important insight into human disease, which can be complemented by animal studies, often in 
models exhibiting phenotypic characteristics observed in human hypertension, which can 
provide mechanistic biological insight into gene function and underlying cardiovascular risk.  
Identification of Quantitative Trait Loci Influencing BP Traits:  
Of the different inbred species used for genetic studies of hypertension, the rat has been 
widely utilized for the identification of QTL using linkage analysis approaches. This has been 
driven by the large number of rat genetic models of hypertension, the relatively low cost of rat 
experimentation, and ease and accessibility of techniques for assessing cardiovascular 
phenotypes in rats. The functional validation of QTL has been enabled by generation of congenic 
or consomic strains, in which defined segments of DNA from one strain are introgressed onto the 
genetic background of a second strain using a genetic marker-assisted breeding strategy. With 
this approach, phenotypic differences detected between the parental and congenic strains can 
indicate that a gene or genes within a particular substituted region of genomic DNA have an 
influence on the functional trait of interest.  The subsequent identification of genes within these 
QTL has been difficult and depends upon complementary approaches including transcriptomic 
analyses, gene sequencing, and gene editing (45, 63).  Development of modern sequencing 
techniques and sequencing of the full rat genome provided further opportunities to fully define 
and design experiments to elucidate key sequence differences of candidate genes within a QTL.   
Epigenetics 
Rodent models have served as excellent platforms to validate the impact of deletion or 
overexpression of individual genes associated with hypertensive traits in GWAS or other linkage 
studies. In addition to their value for genetic and genomic studies, these models have also 
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contributed to recognition of the influence of environmental factors on disease phenotypes, 
including hypertension, fueling the study of epigenetics. Epigenetics refers to effects of 
environmental factors that induce changes in an organism due to modifications in gene 
expression rather than a direct alteration of DNA sequence.  These modifications commonly 
occur through DNA methylation, post-translational histone modifications, and noncoding RNAs.  
Of these factors, DNA methylation has been most studied.  For example, elevated methylation of 
the promoter region of 11-beta HSD2 has been correlated with reduced activity of the enzyme 
and hypertension in patients (265).  Similarly, the promoter of the NKCC-1 is hypomethylated in 
the aorta and heart of SHR compared to the WKY rat, correlating with increased NKCC-1 
activity in those tissues and more severe hypertension (266).  The use of animal models to assess 
epigenetic regulation of gene expression in hypertension promises to be a productive area of 
focus in the future. 
Non-coding RNAs 
RNAs that do not code for proteins can influence disease pathogenesis by regulating the 
effectiveness of gene expression through modulation of messenger RNA (mRNA) levels and 
repression of mRNA translation. Various forms of non-coding RNAs, such as microRNAs, long 
non-coding RNAs, and circular RNAs, have been proposed to play a role in regulation of BP and 
risk for hypertension, and the risk for target organ damage associated with hypertension (88, 267, 
268). While controversy surrounds the appropriate criteria for identifying non-coding RNAs of 
functional significance, there is growing interest in studying them in animal models of 
hypertension, and of hypertension related cardiovascular disorders, from both a mechanistic and 
therapeutic perspective (88, 267-269). Furthermore, non-coding RNAs may be involved in the 
mechanisms of kidney injury in some forms of hypertension (270)     
Microbiome 
Recent studies in humans and animal models have highlighted the powerful impact of the 
microbiome on a range of disorders.  Likewise, the gut microbiota can have a profound influence 
on BP regulation.  In animal models of hypertension, recent observations suggest that there are 
differences in the microbiota between DSS and Dahl R rats (271) and between SHR and WKY 
(272). The mechanisms of action whereby the gut microbiota influence BP are not fully 
elucidated, but the release or stimulation of trimethylamine N-oxide, short chain fatty acids, or 
other factors can influence cardiovascular phenotypes (273, 274). In addition, recent studies have 
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identified specific changes in the gut microbiome influencing blood pressure effects of high salt 
diet (275). As this field matures, it is likely that the influence of the microbiome on complex 
phenotypes such as hypertension will receive wider recognition.  Animal modeling will likely be 
very useful in unraveling these actions. 
Systems Biology:  
The integrated scientific approach to interrogate and understand the contribution of 
individual biological components including genes, transcripts, proteins, metabolites, epigenetic 
modifications, the microbiome, and environmental modifiers, along with the integrated function 
of these components to a cell, tissue, organ, organ system, or organism is termed Systems 
Biology.  Systems Biology approaches utilize high throughput analytical and bioinformatic tools 
to understand the entire system rather than any single individual aspect.  There is no individual 
‘Systems Biology’ approach, nor is there agreement on the precise definition of this approach 
(276, 277), but Systems Biology approaches, integrating quantitative measurement of biological 
variables obtained in animal models, mathematical modeling, reconstruction, and theory (277)  
show great promise for understanding complex multifactorial human diseases like hypertension.  
In summary, studies at the level of genetics, epigenetics, the microbiome, and systems 
biology show great promise for hypertension research. At present, hHowever, due to substantial 
gaps in understanding pathogenesis and genetic determinants of human hypertension, 
opportunities to incorporate relevant causal pathways or genetic variants into animal modeling 
efforts have been limited.  For the same reasons, it has not been possible to utilize molecular 
profiling to verify authenticity of existing animal models. Yet, data emerging from agnostic 
systems biology studies using genetics, genomics, proteomics and analysis of the microbiome 
show promise for advancing basic understanding of human hypertension.  These approaches 
should also allow better validation of animal models based upon identification and recapitulation 
of specific ”omic” signatures derived from human hypertension. 
 
SUMMARY: RELEVANCE OF MODELS TO HUMAN HYPERTENSION: 
CONCORDANCES AND GAPS.  
Animal models of human disorders have proved to be immensely useful in translational 
research in a number of fields, including hypertension.  These models allow incisive approaches 
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not possible in clinical studies for understanding pathophysiology, genetic mechanisms, 
identification of new disease markers and potential therapeutic targets.  As we have highlighted 
in this paper, insights derived from animal models of hypertension have contributed significantly 
to understanding this highly prevalent human disorder.  Here we summarize a few key points that 
are especially relevant for those working in the field. 
Recent high profile publications have decried the poor reproducibility of published studies 
using animal models for pre-clinical assessment of therapeutic agents in human disorders from 
cancer (278) to neurological disease (279). Various factors have been implicated to explain these 
inconsistencies, including: deploying insufficient numbers of experimental animals, inadequate 
power calculations and statistical analyses, assessment of outcomes by individuals who are not 
blinded to experimental groups, and failure to pursue independent replication of critical 
experiments.  Accordingly, these remediable methodological problems must be taken into 
account in designing any study using animal models of hypertension (4-8).   
Another key issue is consideration of how closely the experimental model truly captures what 
is observed in humans (see “construct validity” above).  In this regard, one limitation to 
developing animal models of human hypertension is that the pathogenesis of the human disease 
is not well understood, and the primary cause of elevated BP is not apparent in the vast majority 
of affected individuals.  On the other hand, the cardinal feature of human hypertension, elevated 
BP, can be modeled relatively easily in animals by activating systems known to be involved in 
human hypertension, including the renin-angiotensin system and sympathetic nervous system, or 
inhibition of protective factors, such as nitric oxide. Yet, these models all suffer from their 
limited duration of hypertension compared to humans.  The obscure pathogenesis of human 
hypertension also complicates interpretation and relevance of existing animal models with 
spontaneous hypertension.  Nonetheless, most of these models respond to anti-hypertensive 
therapies used in humans and develop similar long-term complications, suggesting overlaps in 
pathogenesis.  Recent progress in understanding genetic mechanisms of primary hypertension in 
humans should provide opportunities for generating more reliable models, and for analyzing the 
veracity of existing models using systems biology approaches.  
While elevated BP is the key diagnostic feature of human hypertension, its morbidity and 
mortality result from complications in the brain, heart, kidney and vasculature.  The contribution 
of elevated BP to these complications has been well established in clinical trials showing that BP 
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lowering reduces complications.  However, understanding the molecular mechanisms of these 
complications is an unmet need, where animal models should continue to add value through 
identifying pathways and/or markers associated with increased risk for complications, 
understanding mechanisms for known risk factors such as APOl1, and for potentially identifying 
therapies that can protect against complications, above and beyond blood pressure control. 
Another key feature of human hypertension is its frequent association with chronic co-
morbidities such as obesity, diabetes, heart and kidney disease, which can influence the disease 
characteristics and outcomes. Likewise, sex and ethnicity also have major impact in human 
hypertension.  These factors are not typically incorporated into most animal models of 
hypertension, but should be to improve concordance with the human condition. 
The choice of a suitable model, such as small versus large animal, spontaneous versus 
induced hypertension, etc., will depend on a number of factors including the specific 
experimental question and an investigator’s available resources and expertise.  No individual 
model will recapitulate all features of human hypertension, and all have advantages and 
shortcomings, which we have highlighted in this manuscript and its accompanying tables.  These 
factors obviously must be taken into account in the design and interpretation of experiments, and 
the most powerful insights will often be derived from studies carried out in multiple, 
complementary models. 
CONCLUSIONS  
Hypertension is the most common chronic disease in the world, and increased understanding 
of the pathogenesis, prevention, and treatment of hypertension and its comorbidities is 
imperative. Animal models of hypertension have been, and will likely remain, very useful in 
provide insights into the pathogenesis and novel treatment options of hypertension. Clearly, 
investigators need to make informed choices as to the appropriate animal model for specific 
application, and the experiments need to be carefully designed, executed, and interpreted. In this 
Statement we summarize a few key points that are especially relevant for those working in the 
field, and may aid in propelling it forward. 
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Table A. Examples of transgenic techniques related to hypertensive models 
 Small animal models Large animal models 
Transgenic technique Species Examples 
Gene over-expression M 
M/R 
Mendelian models of hypertension 
Salt-sensitive hypertension (120, 130) 
Inducible expression R Inducible hypertension & end organ damage (118) 
BAC incorporation M Reduced risk of hypertension (76, 77) 
Global gene knockout/  M 
M/R 
M 
Mendelian models of hypertension (105-109) 
Salt-sensitive hypertension (110-112, 128-130) 
Pulmonary hypertension (280) 
Renin hypotension (113-115) 
Gene knock-in M/R Renin  (119); RAS humanization (122, 123) 
Targeted gene knockout M Kidney specific Hsd11b2 knockout (111) 
Safe haven targeting R ROSA 26 (93, 94) 
Conditional knockout M Pulmonary hypertension (124, 125) 
Rat / rabbit ES cells R 
Rb 
TALEN targeting (281) 
ApoE knockout (82) 
Zinc finger nucleases R Salt-sensitive hypertension (86) 
TALENs M/R Pde1a(87) 
CRISPR-Cas9 R (88); Humanisation & ROSA-26 (93, 94) 
Gene knock-down/ 
Anti-miRs / siRNA 
M/R AT1A receptor (126); Reduced hypertension in 
aldosterone/salt treated mice (127); Reduced 
hypertension in SHR (95). 
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Anatomical, physiological, 
hemodynamic properties 
Distant from humans  Closer to humans 
Developmental pathophysiology Distant from humans  Closer to humans 
Tissue availability Low High 
Costs Low High 
Genetic modification Readily available Possible 
Reproductive cycle Short Long 
Characterization Extensive Adequate 
Availability of specific antibodies High Low 
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Table B. Sex Differences in Blood Pressure and Response to Treatment in Animal models 
 Males Females 
Strain/model Young adult Aging Young adult Aging (post 
cycling) 
SHR     
No treatment M > F M ≤ F F < M F ≥ M 
ETAR 
antagonism 
No effect No effect  No effect Modest fall 
 Enalapril/losartan Normalize  Normalize  Normalize  Decrease 
20-HETE  Yes  No effect Decrease F > 
M 
Gonadectomy Castrated < M Castrated < M No effect. OVX = 
F 
No effect. 
OVX= F 
Adrenergic block/ 
renal denervation 
Decrease M>F Decrease Decrease Decrease 
MC4R antagonist Decrease Decrease No effect No effect 
Nitric oxide NOx/NOS1/NOS
3 activities M < F 
E2 increase eNOS 
synthesis 
  
Antioxidants  Decrease Decrease If start pre-puberty No effect 
T cells   Tregs F > M  
Pregnancy   Falls last trimester  
Dahl S     
  Low NaCl M > F Rise with aging F < M Rise with 
aging 
+ High NaCl diet M > F    
    
Gonadectomy 
Castrated < M  Castrated < M OVX > F Ovx=F rise 
with age 
      Pregnancy   No fall last 
trimester 
 
mREN2     
    No 
treatment 
M > F  F < M  
    
Gonadectomy 
Castrated < M  OVX > F OVX = F 
Normotensive 
strains 
    
No treatment 
(rats) 
M > F M < F F < M F ≥ M by 18 
mos 
    + DOCA-
salt 
M > F    
    + Ang II      
            + ACEI M > F (mice)  F > M (rats)  
           - ACEI M > F (mice/rats)    
+ACEI + high 
NaCl  
M = salt sensitive  F =not salt 
sensitive 
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T cells M > F  F < M  
     Pregnancy   Decrease late   
           + RUPP   Increase late   
         + L-
NAME 
  Increase  
Offspring effect 
 RUPP dams 
M > F Normalizes F < M Increase F 
> M 
Obesity (mice) M > F  No effect   
Rabbits M > F   F < M  
Dogs + Ang II Increase M > F  Increase F < M  
Chickens M > F  F < M  
SHR, Spontaneously hypertensive rats; M, male; F, female; OVX, ovariectomized female; 
ETAR, endothelin-A receptor; MC4R, melanocortin 4 receptor; DOCA, deoxycorticosterone 
acetate; Ang II, angiotensin II; ACEI, angiotensin I converting enzyme; NOS, nitric oxide 
synthase; RUPP, reduced uterine perfusion pressure; L-NAME, nitro-L-arginine methyl ester.  
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Table C. Cerebrovascular pathologies in selected animal models of hypertension 
Hypertension model Species Neurovascular pathology References 
AngII infusion 
(2-4 weeks) 
Mouse 
Rat 
• Hypertrophy and remodeling 
• Neurovascular dysfunction 
• Increased BBB permeability 
• Inflammation 
• Oxidative stress 
• Cognitive deficits 
• Brain amyloid eta accumulation 
(282-286) 
Chronic AngII+Acute 
AngII+LNAME 
Mouse • Micro-hemorrhages 
• Increased BBB permeability 
• Inflammation 
• Cognitive deficits 
(287, 288) 
Ren and/or Agt 
overexpression 
Mouse 
Rat 
• Hypertrophy and remodeling 
(R+/A+ mouse) 
• Increased stiffness (Renin rat) 
• Endothelial dysfunction 
• Cognitive deficits (R+/A+ mouse) 
• Larger infarcts (after MCAO) 
(289-293) 
Ren/Agt 
overexpression 
+LNAME +High salt  
Mouse • Micro-hemorrhages 
• Inflammation  
• Oxidative stress 
(294) 
ET1 overexpression in 
endothelial 
cells+MCAO 
Mouse • Larger infarcts 
• Increased BBB permeability 
• Cognitive deficits 
(295, 296) 
eNOS deficiency 
LNAME hypertension 
Mouse 
Rat 
• Hypertrophy 
• Endothelial dysfunction 
• Larger infarcts (after MCAO) 
(297-300) 
Chronic intermittent 
hypoxia/obstructive 
sleep apnea 
Mouse 
Rat 
• Neurovascular dysfunction 
• Oxidative stress 
• Larger infarcts (after MCAO) only 
with more severe cyclic hypoxia 
(6%O2) 
(301-305) 
BPH2 Mouse • Hypertrophy 
• Neurovascular dysfunction 
• Increased BBB permeability 
• Cognitive deficits 
(283, 290, 
306) 
SHR-SP+Western diet Rat • Infarcts and hemorrhages 
• Neurovascular dysfunction 
• Increased BBB permeability 
• Retinopathy 
(307-309) 
SHR+MCAO Rat • Larger infarcts (310, 311) 
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SHR-SP+Carotid 
occlusion 
Rat • White matter lesions 
• Increased BBB permeability 
• Inflammation 
• Cognitive deficits 
(312) 
Dahl Rat+High salt Rat • Oxidative stress 
• Reduced BBB marker proteins 
• Increased BBB permeability 
• Loss of myogenic tone 
• Infarcts and hemorrhages 
(15, 313, 
314) 
DOCA salt Mouse 
Rat 
• Hypertrophy  
• Neurovascular dysfunction 
• Inflammation 
• Oxidative stress 
• Cognitive deficits 
• No change in infarct size or larger 
infarcts (after MCAO) 
(286, 315-
318) 
• DOCA salt+elastase 
• AngII (2 weeks)+ 
elastase 
• Carotid & renal 
artery 
ligation+AngII (2 
weeks) +elastase 
Mouse • Cerebral aneurysms formation and 
subarachnoid hemorrhage 
 
(316, 319, 
320) 
Renovascular 
hypertension  
Rat • Infarcts and hemorrhages  
• Larger lesions (after MCAO) 
(321, 322) 
Aortic coarctation 
 
Mouse 
 
• Hypertrophy 
• Endothelial dysfunction 
• Oxidative stress 
• Brain amyloid eta accumulation 
• Cognitive impairment 
(323, 324) 
 
Yucatan 
pig 
 
• Vascular stiffening 
• Cognitive deficits 
(325, 326) 
 
Cynomol
gus or 
Rhesus 
monkey 
• White and gray matter microinfarcts 
(<1mm) 
• Cognitive deficits 
(327) 
Aortic coarctation+ 
High fat diet±aging 
Cynomol
gus or 
Rhesus 
monkey 
• Worse cognitive deficits (328, 329) 
AngII: angiotensin-II; BBB: blood-brain barrier; BPH2: blood pressure high-2; DOCA: 
deoxycorticosterone acetate; LNAME: Nitro-L-arginine-metylester; MCAO: middle cerebral 
artery occlusion; Ren/Agt: renin angiotensinogen; SHR-SP: stroke-prone spontaneously 
hypertensive rats; elastase injected in the basal cistern
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Table D. Vascular target organ damage in different experimental models of hypertension 
Hypertension model 
Vascular target organ damage  Reference 
Genetic rat models   
SHR Inward eutrophic remodeling (resistance artery) 
Hypertrophic remodeling (conduit artery) 
Rarefaction  
Endothelium-dependent dysfunction 
Impaired endothelium-independent vasorelaxation 
(conduit arteries) 
(330-335) 
 
SHRSP 
 
Hypertrophic remodeling   
Fibrosis 
Vascular hypercontractility 
Endothelial dysfunction 
Increased myogenic tone 
 
(336, 337) 
GHR Hypotrophic outward remodeling (basilar artery) (338) 
   
Salt-sensitive hypertension   
   
DSS Hypertrophic remodeling   
Endothelial dysfunction 
Impaired myogenic response (cerebral artery) 
(51, 339-
341) 
DOCA-salt Hypertrophic remodeling   
Endothelial dysfunction 
Vascular inflammation 
 
(333, 342) 
   
Renovascular   
   
One-clip Goldblatt Inward eutrophic remodeling (resistance artery)  
Hypertrophic remodeling (conductance artery) 
(343) 
2K-1C   
Hypertrophic remodeling (aorta but not mesenteric 
artery) 
 
(344) 
   
NO-dependent models   
   
L-NAME Outward hypotrophic remodeling   
Aortic stiffness  
Increased pulse wave velocity  
Impaired endothelium-independent vasorelaxation  
Cerebral artery remodeling 
(345-348) 
SHR/L-NAME Aortic stiffness    
Reduced distensibility 
Excessive fibrosis 
(349) 
   
Ang II-dependent models   
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Ren-2-transgenic rats Aortic endothelial dysfunction   
Decreased aortic contraction  
Fibrosis 
Endothelial dysfunction 
(350) 
dTGR Medial hypertrophy  
Intimal thickening 
Fibrinoid necrosis 
(351) 
Ang II-infused (400 
ng/kg/min; Slow pressor) 
Inward eutrophic remodeling  
Endothelial dysfunction 
Vascular hypercontractility 
Low-grade vascular inflammation 
(160-163) 
(352-354) 
Ang II-infused   
(>1000 ng/kg/min) 
Aortic medial thickening    
Outward aortic remodeling  
Vascular inflammation 
Vascular hyper-reactivity 
Increased vascular tone  
Increased aortic stiffness 
Endothelial dysfunction 
(355-358) 
   
Large mammals      
AGM  Renal vascular remodeling  
Vascular hypertrophy 
(141, 359) 
Hypertensive obese pig Cardiac microvascular remodeling (360) 
Fat-fed mini-pig Endothelial dysfunction   
Vascular inflammation 
Hypertrophic remodeling 
(361) 
 
     
SHR, spontaneously hypertensive rat; DSS, Dahl salt-sensitive; SHRSP, stroke-prone SHR; 
GHR, genetically hypertensive rat; DOCA, deoxycorticosterone; NO, nitric oxide; L-NAME, 
Nω-nitro- L-arginine methyl ester; Ang II, angiotensin II; Ren, renin; agm, African green 
monkey; 2K-1C, two-kidney, one-clip; dTGR, human renin-angiotensinogen 
double transgenic rat. 
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